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Abstract 
The alarming rate of increase in incidence and prevalence of the type 2 
diabetes mellitus has prompted intense research on understanding the 
pathogenesis of the type 2 diabetes.  It is observed that the development of 
type 2 diabetes is preceded by a state of insulin resistance and obesity.  
Previous studies have suggested that the obesity induced insulin resistance 
may be mediated by elevated levels of circulating free fatty acids (FFAs).  The 
increase in circulating levels of FFAs may be contributed by the release of 
FFAs from stored triglycerides (TG) in adipocytes via lipolysis.  It is 
hypothesized that the decrease in levels of circulating FFAs by sequestration 
and storage of FFAs in adipocytes may prevent deleterious effects of FFAs 
on insulin sensitivity.  Recently our lab and others have shown that the 
storage of TG in adipocytes is promoted by a novel protein, Fat Specific 
Protein 27 (FSP27).  Although, these studies also revealed FSP27 to be a 
lipid droplet associated protein that suppresses lipolysis to enhance TG 
accumulation in adipocytes, the role of FSP27 in lipolysis remains largely 
undetermined.  Therefore, this study investigates the role and regulation of 
FSP27 in adipocytes in both the basal state, as well as during lipolysis.  
 
The studies presented here show FSP27 to be a remarkably short-lived 
protein (half-life=15 min) due to its rapid ubiquitination and proteasomal 
degradation.  Thus, I tested the hypothesis that lipolytic agents like the 
  vii 
cytokine, TNF-α and the catecholamine isoproterenol modulate FSP27 
protein levels to regulate FFA release.  Consistent with this concept, TNF-α 
markedly decreased FSP27 mRNA and protein along with lipid droplet size as 
it increased lipolysis in cultured adipocytes.  Similarly, FSP27 depletion using 
siRNA mimicked the effect of TNF-α to enhance lipolysis, while maintaining 
stable FSP27 protein levels by expression of HA epitope-tagged FSP27 
blocked TNF-α mediated lipolysis.  In contrast, the robust lipolytic action of 
isoproterenol is paradoxically associated with increases in FSP27 protein and 
a delayed degradation rate that corresponds to decreased ubiquitination.  
This catecholamine-mediated increase in FSP27 abundance, probably a 
feedback mechanism to restrain excessive lipolysis by catecholamines, is 
mimicked by forskolin or 8-Bromo-cAMP treatment, and prevented by Protein 
Kinase A (PKA) inhibitor KT5720 or PKA depletion using siRNA.  These 
results show that isoproterenol stabililizes FSP27 via the canonical PKA 
pathway and increased cAMP levels.  However, the work presented here also 
suggests that FSP27 does not get phosphorylated in response to 
isoproterenol treatment, and the stabilization of FSP27 is independent of 
isoproterenol mediated lipolysis. 
 
The data presented in this thesis not only identifies the regulation of FSP27 
as an important intermediate in mechanism of lipolysis in adipocytes in 
  viii 
response to TNF-α and isoproterenol, but also suggests that FSP27 may be a 
possible therapeutic target to modulate lipolysis in adipocytes. 
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Chapter I 
INTRODUCTION 
The scientific and technological advancement providing increased availability 
of food and a decreased need for physical work have shaped the present day 
human niche of overfeeding and under utilization of consumed calories.  As a 
result, obesity and its subsequent result – Diabetes Mellitus are increasing at 
such alarming rates that both obesity and diabetes have become pandemic.  
According to the 2007 National Diabetes Fact Sheet (published on American 
Diabetes Association website, http://www.diabetes.org/diabetes-
basics/diabetes-statistics/), 7.8% of the population in the United States has 
diabetes, and 1.6 million new cases of diabetes are diagnosed each year 
among people aged 20 yr and older.  Even more disturbing is the trend that 
obesity and diabetes are becoming more prevalent in children and 
adolescence.  It is estimated that 0.22% of the people in this age group have 
diabetes.  In addition to the health problems, the management of diabetes 
imposes a huge economic burden. In 2007, the total cost of diagnosed 
diabetes was $174 billion in the United States alone.  Therefore, obesity and 
diabetes are the nation’s current major medical burdens.   
 
Diabetes mellitus is a disorder of glucose homeostasis.  The human body 
maintains the healthy serum glucose level of 4-7 mM through a balance 
between the input of glucose into the circulation from feeding, and the output 
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of glucose from the circulation by uptake and utilization by various tissues.  
Although, the maintenance of normal blood glucose is regulated by various 
hormones, the critical hormone required for glucose homeostasis is insulin.  
Any disturbance in the level of insulin or its function is the key to the 
development of diabetes.  There is insulin deficiency in type I diabetes 
mellitus where as there is insulin resistance in type II diabetes mellitus.  Both 
insulin deficiency as well as insulin resistance result in high glucose levels 
that become toxic to various tissue, thus giving rise to complications such as 
blindness, end-stage renal disease, and non-traumatic loss of limb (1). 
 
The development of type II diabetes is related to a heritable genetic aspect as 
well as to the modifiable environmental factors such as diet and exercise.  A 
study involving the Malmo Preventive Project and Botnia study in Finland 
consisting of 18,831 people showed the increased association of family 
history of diabetes in first-degree relatives, and genetic risk alleles to the 
development of diabetes.  It also showed a higher incidence of diabetes in 
people when the genetic risk was combined with environmental factor such as 
obesity (2).  The extensive study of the development of diabetes in obesity 
has suggested inflammation and FFAs as important mediators in obesity 
related diabetes, but the underlying mechanisms are yet to be fully 
understood.  Unraveling these mechanisms will help to elucidate their role in 
the progression from obesity to diabetes.  This understanding is important, as 
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it can provide a basis for newer and better therapies in the treatment and cure 
for diabetes. 
 
Adipose Tissue: An endocrine organ 
There are two different types of adipose tissues in humans and rodents: 
brown adipose tissue (BAT) and white adipose tissue (WAT).  BAT, named 
because of its brown color, has a thermogenic function.  BAT was previously 
thought to be present only in infants, however, recent evidences have shown 
that there are brown adipocytes interspersed in WAT in adult humans (3).  
WAT on the other hand, is a soft, yellowish tissue that forms a few large 
depots in the body mainly subcutaneous and visceral in location.  But there 
are also smaller depots present in the heart, large blood vessels, lymph 
nodes, bone marrow, kidney, adrenal gland, and the brain (4).  WAT is 
comprised mainly of adipocytes or fat cells, along with stromal vascular cells 
consisting of fibroblasts, stem cells, and inflammatory cells (5).  This thesis 
focuses on WAT and white adipocytes herein referred to as adipocytes. 
 
Adipogenesis 
The differentiation of adipocytes from fibroblasts with adipogenic potential is a 
complex process known as adipogenesis.  Adipogenesis is predominantly 
controlled by peroxisome proliferator-activated receptor γ (PPAR γ) that is 
now considered the master regulator of adipogenesis (6, 7).  PPARγ is a 
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transcription factor that is activated by various endogenous ligands such as 
polyunsaturated fatty acids, prostaglandin J2, as well as exogenous ligands 
such as ibuprofen, indomethacin, and chiefly thiazolidinediones (TZDs) (8-
11).  Although PPARγ is considered the most important transcription factor, 
the process of adipocyte differentiation starts with the expression of two other 
transcription factors: C/EBPβ and C/EBPδ, that induce the expression of 
PPARγ and C/EBPα.  PPARγ and C/EBPα act as a positive regulator of each 
other, and the high expression of these transcription factors is detected in 
terminal differentiation of adipocytes (7, 12). PPARγ drives the expression of 
many adipocyte genes such as lipoprotein lipase (LPL) (13), 
phosphoenolpyruvate carboxykinase (PEPCK) (14), acyl-CoA synthetase 
(ACS) (15), perilipin (16), and Cell Death-Inducing DFFA-like Effector A 
(CIDEA) (17).  These PPARγ target genes, especially the ones involved in 
lipogenesis and lipid storage, ultimately direct adipocytes towards storing 
FFAs as triglycerides in lipid droplets. 
 
Endocrine Functions of Adipose tissue 
It is well known that adipocytes in WAT store excess energy derived from 
ingested food in their lipid droplets (18), but with the groundbreaking 
discovery of Leptin in 1995 (19), the role of WAT as an endocrine organ has 
started to emerge.  In addition to leptin, WAT also secretes other hormones 
such as adiponectin, resistin, omentin, chemerin, retinol binding protein 4, 
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vaspin, and visfatin. These hormones secreted by WAT are collectively called 
adipokines.  Studies on adipokines have supported their role in regulation of 
glucose and lipid metabolism, inflammation, atherosclerosis, hemostasis, and 
blood pressure (5).  Furthermore, lipodystrophy, a disorder of adipose tissue 
formation, is associated with the insulin resistance and type 2 diabetes 
mellitus (20-23) , thus reinforcing the importance of the endocrine functions of 
adipose tissue. 
 
Adiponectin (Acrp30) 
One of the important adipokines is adiponectin, a 30-kDa protein secreted 
from adipocytes from an intermediate stage of adipogenesis onwards (24, 
25).  A deficiency of adiponectin in vivo has been shown to lead to insulin 
resistance (26-28) whereas increased adiponectin in transgenic mice has 
been associated with insulin sensitivity (29) and suppression of endogenous 
glucose production (30).  There is also an association between reduced 
plasma adiponectin with obesity and insulin resistance in mice suggesting a 
role of adiponectin in insulin sensitivity (25, 31).  The role of adiponectin in 
regulating whole body insulin sensitivity is further supported by the studies 
that show administration of recombinant adiponectin to rodents increases 
glucose uptake and fat oxidation in muscle, and decreases glucose 
production from liver (32-34).  In addition to the insulin sensitizing effects in 
adipocytes, muscle, and liver, the global effect of adiponectin could also be 
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due to increased insulin secretion from the pancreas (35), and to the 
modification of food intake and energy expenditure through its actions in 
central nervous system (CNS) (36). 
 
Adiponectin secreted from adipocytes circulates in plasma as a trimer, 
hexamer or 12- to 18-mer, and each form is thought to have a different 
activity (37, 38).  The effects of adiponectin are mediated through adiponectin 
receptors 1 and 2 (AdipoR1 and AdipoR2), both ubiquitously expressed but 
AdipoR1 is expressed predominantly in skeletal muscle while AdipoR2 is 
expressed more in liver (39, 40).  Research investigating the mechanism of 
adiponectin actions suggest that activation of adiponectin receptors activates 
AMP-activated protein kinase (AMPK), and increases expression of PPARα 
target genes such as acyl-coenzyme oxidase, and uncoupler protein (UCP2) 
to increase fatty acid oxidation and energy expenditure (41). 
 
Consistent with the data in animal models, the levels of circulating 
adiponectin in humans is negatively correlated with the insulin resistance (42-
44), and type 2 diabetes (42, 45).  In addition to this, single nucleotide 
polymorphisms (SNPs) in adiponectin gene have been reported to be 
associated with insulin resistance and type 2 diabetes mellitus (46).  TZDs 
(anti-diabetic, therapeutic agent) are also known to cause increases in the 
expression and secretion of adiponectin (47-49). Taken together, these data 
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indicate that adiponectin is an important adipokine with a role in insulin 
sensitivity. 
 
Leptin 
Leptin is another adipokine that has been shown to regulate food intake and 
energy expenditure.  The deficiency of leptin has been reported to lead to 
obesity and insulin resistance in rodents as well as humans.  The effects of 
leptin were first observed in 1950 when a random mutation in a gene 
produced obese mice (ob/ob) within a colony at Jackson Laboratory (50).  
The gene ‘Ob’ itself was cloned only in 1994 (51), and the ‘Ob’ gene product- 
Leptin and its effect on feeding and energy expenditure were discovered in 
1995 (19). 
 
Circulating leptin, a small 16 KDa protein, is able to cross the blood-brain-
barrier to act on the arcuate nucleus, a region of the hypothalamus in the 
central nervous system.  Prior evidences suggest that stimulation of the leptin 
receptor by leptin activates the JAK-STAT signaling pathway that regulates 
food intake and body weight, as well as PI3K signaling pathway that regulates 
glucose metabolism.  Because, leptin stimulates two different pathways to 
regulate body weight and glucose metabolism, mice with the mutation in the 
leptin  receptor (db/db)  can’t  activate the  JAK-STAT   pathway  but  can  still   
signal   through  the  PI3K  pathway.  These  db/db  mice  are  obese  and  
  8 
 
Adipokine Function Adiponectin  ↑Insulin sensitivity; ↑Insulin secretion from pancreas, Leptin  ↓ food intake; ↑Insulin sensitivity; prevents ectopic lipid accumulation in liver and muscle Omentin  ↑Insulin sensitivity Chemerin  Conflicting results on insulin sensitivity, needs further investigation Vaspin  ↑Insulin sensitivity Resistin  ↑Insulin resistance; ↓ Insulin sensitivity Retinol Binding Protein 4  ↑Insulin resistance; ↓ Insulin sensitivity Visfatin  ↑Insulin resistance; ↓ Insulin sensitivity; conflicting results in humans Inflammatory Cytokines (TNF‐α, IL‐6, MCP‐1)  TNF‐α & IL‐6: ↑Insulin resistance; ↓ Insulin sensitivity; MCP‐1: ↑ Macrophage infiltration in adipose tissue 
 
Table 2.1: List of adipokines and their effect on insulin sensitivity
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hyperphagic due to the defect in JAK-STAT pathway, but have only mild 
glucose intolerance that can be corrected with calorie restriction (5).  
 
In addition to the actions of leptin via CNS, the insulin sensitizing effect of 
leptin may also mediated by prevention of ectopic lipid accumulation in liver 
and muscle (52, 53).  Studies have also shown that leptin protects the 
pancreas from lipid accumulation caused by a high calorie diet and promotes 
its function, in addition to inhibiting insulin secretion in lean animals (54).  
 
The secretion of leptin is observed to be proportional to the adipose tissue 
mass, and thus there are higher levels of leptin in obese individuals compared 
to the lean ones.  However, chronic elevation of leptin has been shown to 
have attenuated effects on improving insulin sensitivity despite the presence 
of a functional leptin receptor, that indicates the development of leptin 
resistance in presence of persistent high levels of circulating leptin (55).  
Thus, the maintenance of leptin levels, as well as leptin receptor function is 
important to regulate food intake, body weight, and insulin sensitivity. 
 
Omentin 
Omentin is an adipokine that has not been well characterized but has been 
shown to increase insulin stimulated glucose transport and AKT 
phosphorylation in human subcutaneous and visceral adipocytes.  It is 
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secreted by the visceral stromal vascular cells. The levels of omentin 1, the 
major isoform of omentin present in plasma, is found to negatively correlate 
with adiponectin and HDL levels (5).  Although it has been postulated that 
omentin plays a role in enhancing insulin sensitivity, the mechanism of this 
adipokine has yet to be uncovered.  
 
Chemerin 
The most recently discovered adipokine is Chemerin.  It is highly expressed in 
liver and white adipose tissue (56, 57) and is upregulated during 
adipogenesis (58).  Previous studies in 3T3-L1 adipocytes have shown that 
chemerin increases insulin-stimulated glucose uptake and IRS1 
phosphorylation, whereas studies in activated macrophages expressing 
chemerin receptor have shown that chemerin has an anti-inflammatory effect 
(5).  Rodent and human studies have revealed conflicting results regarding 
the role of chemerin in diabetes.  Db/db mice have been shown to have 
decreased chemerin in adipose tissue compared to the controls, whereas 
chemerin is increased in adipose tissue from glucose intolerant and diabetic 
sand rat  (56, 59).  In humans, chemerin did not correlate with type 2 diabetes 
but in normal glucose tolerant subjects, chemerin levels have been 
associated with BMI, triglycerides, and blood pressure (56).  Due to these 
conflicting results, the role of chemerin in insulin sensitivity remains to be 
verified and explored further. 
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Vaspin 
Vaspin or visceral adipose tissue-derived serine protease inhibitor is an 
adipokine identified in visceral adipose tissue of Otsuka Long-Evans 
Tokushima fatty rat (OLETF), a new non-insulin dependent diabetes mellitus 
rat model.  Vaspin levels decrease with the increasing body weight and 
glucose intolerance, whereas administration of recombinant vaspin to diet-
induced obese rodents improves glucose tolerance and insulin sensitivity 
suggesting a positive correlation of vaspin with insulin sensitivity (5).  
Although, similar insulin sensitivity enhancing results of vaspin have been 
reported in humans, the full characterization of vaspin, and its functions have 
yet to be undertaken.  
   
Resistin    
Some of the adipokines secreted by adipocytes have deleterious effect on 
insulin sensitivity. One such adipokine is resistin, a 12 kDa peptide 
discovered during an examination of TZDs responsive genes in 2001 (60).  
Resistin has been reported to increase during adipogenesis as well as in 
insulin-resistant mice, and decrease upon TZDs treatment of mice.  
Moreover, antiresistin antibody treatment has been shown to improve insulin 
sensitivity and glucose transport in vitro and in vivo (61).  
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In humans, resistin has been shown to be expressed by macrophages.  
Studies investigating the association between resistin levels and insulin 
resistance in humans have shown variable results.  However, resistin levels 
decrease after therapeutic treatment of diabetic patients with TZDs and 
metformin suggesting a role of resistin in insulin resistance in humans also 
(61). 
 
Retinol Binding Protein 4 
Retinol Binding Protein 4 or RBP4 is another adipokine with deleterious 
effects on insulin signaling and has been identified as a highly expressed 
circulating adipokine in insulin-resistant, adipose specific GLUT4 knockout 
mice and humans with obesity, and type 2 diabetes  (62).  It is expressed 
mainly in visceral adipose tissue supporting the hypothesis that visceral 
adipose tissue is associated with insulin resistance (63).  In addition, 
correlation between serum RBP4 with RBP4 mRNA expression, visceral fat 
mass, total body fat mass, and insulin resistance has been reported (64).  In 
vivo studies have shown that RBP4 overexpression or recombinant RBP4 
induces insulin resistance whereas RBP4 deletion improves insulin sensitivity 
(5).  However, other studies have failed to show any correlation of RBP4 with 
insulin resistance or obesity (61).  Although these inconsistencies may be due 
to differences in patient populations or methodology, further studies are 
required to comprehend the features of RBP4. 
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Visfatin/PBEF/NAMPT 
Visfatin is an adipokine that has been originally identified as a cytokine that 
promotes B cell maturation.  Visfatin has been proposed to have a role in 
obesity and insulin resistance on the basis of studies in animal models.  In 
mice, injection of visfatin decreases blood glucose levels whereas visfantin 
mutation leads to higher glucose levels.  However, the role of visfatin in 
insulin resistance in humans is not clear due to conflicting results among 
different studies examining the plasma visfatin levels and obesity, insulin 
resistance and type 2 diabetes (5, 61).  Therefore, further exploration is 
required to assess the role of visfatin in insulin sensitivity. 
 
Inflammatory Cytokines  
Adipose tissue is also a source of inflammatory cytokines such as TNF-α, IL-
6, and Macrophage Chemoattractant Protein 1 (MCP-1). The role of TNF-α in 
the development of insulin resistance has been extensively studied, and is 
discussed in detail later in this thesis.  Although, the association of IL-6 with 
obesity is not clear, some of the studies have shown the association of 
increased levels of IL-6 with impaired glucose disposal and insulin resistance.  
It has been speculated that IL-6 induces insulin resistance through cytokine 
signaling (SOCS) 1 and 3 that promotes Insulin Receptor Substrate (IRS) 
degradation (65).  In addition to these inflammatory cytokines, adipose tissue 
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also secretes MCP-1, a chemokine that act as a chemoattractant to recruit 
macrophages to the adipose tissue.  However, data on necessity of MCP-1 
for macrophage infiltration in adipose tissue is conflicting.  Kanda and 
colleagues have shown increased macrophage infiltration in adipose tissue 
and insulin resistance in MCP-1 expressing transgenic mice whereas MCP-1 
deficient mice exhibited decreased macrophage infiltration in adipose tissue 
and improved insulin sensitivity when fed on the high fat diet (66).  On the 
other hand, Inouye and colleagues have noted no difference in the number of 
macrophages recruited to the adipose tissue in MCP-1 deficient mice fed on 
high fat diet compared to the control mice (67). 
 
Lastly, adipose tissue has also been shown to secrete Plasminogen Activator 
Inhibitor 1 (PAI-1).  PAI-1 is expressed in the stromal vascular fraction of 
adipose tissue, and endothelial cells, and has been reported to increase in 
obesity.  Prior evidences have supported the pro-thrombotic effects of PAI-1 
due to its inhibitory action on plasminogen activators.  PAI-1 has recently 
been linked to TSP1 expression in adipocytes.  TSP1 is also thought to 
function as an adipokine, and has been observed to increase in obese, insulin 
resistant subjects with increased adipose tissue macrophage infiltration (61). 
 
Thus, adipose tissue function is considerably more vast and complex than 
previously thought and actually functions as a full-fledged endocrine organ.  
  15 
Moreover, the hormones secreted by adipose tissue interplay with one 
another, as well as with other tissues, and respond to nutrition to maintain 
glucose homeostasis.  For example, adiponectin and TNF-α regulate the 
synthesis and activity of one another.  Excess calorie intake and obesity have 
been theorized to activate inflammatory pathways that suppress adiponectin 
and increase inflammatory cytokines that ultimately lead to the disturbance of 
insulin signaling. 
 
Insulin Signaling 
Although adipokines play an important role in glucose metabolism, the most 
important hormone for glucose homeostasis is insulin.  The isolation of insulin 
in 1921 was the greatest discovery that formed a foundation for future studies 
on glucose metabolism (68), in addition to providing a therapy for patients 
suffering from diabetes.  Insulin is a small peptide hormone containing only 51 
amino acids, and is secreted from the pancreas.  The ability of insulin to lower 
blood glucose has been known for a long time, and the mechanism of insulin 
action on metabolism has been investigated intensely, yet complete 
understanding of the insulin signaling pathways and functions, has remained 
elusive. 
 
The actions of insulin on insulin-target tissues mainly adipocytes, muscle, and 
liver, are mediated through the insulin receptor (IR).  The IR is a 
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transmembrane tyrosine kinase receptor that upon insulin stimulation 
undergoes a conformational change, and autophosphorylation at multiple 
tyrosines (69-71).  The phosphorylated tyrosines in the IR recruits scaffolding 
proteins, like IRS 1-4, that further recruit the downstream effector molecules 
(72-76).  IRS1 and IRS2, bind the downstream signaling molecule – type 1A 
phosphatidylinositol 3-kinase (PI3K) (77) via its regulatory subunit (p85), and 
the binding of p85 to phosphorylated IRS activates the catalytic subunit of 
PI3K.  The activated PI3K phosphorylates many phosphoinositides (PI), 
however type 1A PI3K preferentially phosphorylates PI (4,5) P2 to form PI 
(3,4,5)P3 that further recruits another serine/threonine kinase – 3-
phosphoinositide-dependent protein kinase-1 (PDK1) (78-82).  PDK1 together 
with PI3K is responsible for phosphorylation of another serine/threonine 
kinase – AKT/ Protein Kinase B (PKB) (83).  AKT/PKB is also phosphorylated 
at Ser473, a site different from PDK1 phosphorylated Thr308, by a newly 
discovered protein kinase – mammalian target of rapamycin (mTOR) together 
with its regulatory subunit – RICTOR (84, 85).  The signaling cascade 
downstream of AKT/PKB has been extensively studied, and plays vital role in 
the regulation of glucose transport, glucose and glycogen metabolism, 
lipolysis and lipogenesis, protein synthesis, and specific gene expression 
(86). 
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Regulation of glucose transport 
The activation of AKT/PKB after insulin stimulation plays the key role in 
enhancing glucose uptake by increasing translocation of the glucose 
transporter GLUT4 from the cytosol to plasma membrane in insulin target 
tissues such as adipocytes and muscle.  Among many glucose transporters, 
GLUT4 is the insulin responsive glucose transporter present in adipocytes 
and muscle, and the deficiency of GLUT4 specifically in the adipose tissue or 
muscle leads to insulin resistance in mice (87-89).  GLUT4 mostly resides in a 
perinuclear storage site in the basal state (72, 90).  However, insulin 
stimulation causes rapid exocytosis of GLUT4 vesicles from the perinuclear 
site to the plasma membrane.  In addition, insulin also inhibits endocytosis of 
GLUT4 from the plasma membrane into the cytosol.  Thus, an insulin-
stimulated increase in exocytosis and a decrease in endocytosis of GLUT4 
causes a dramatic increase of GLUT4 at the plasma membrane (72, 91-94).  
The increase of GLUT4 at the plasma membrane after insulin stimulation is 
also due to the inhibition of AS160.  AS160 is a RAB-GAP protein that 
promotes intracellular retention of GLUT4 in the basal state.  Upon insulin 
stimulation, AKT/PKB phosphorylates and inactivates AS160, thus allowing 
GLUT4 translocation to the plasma membrane (95, 96).  The process of 
GLUT4 translocation to the plasma membrane is dependent upon 
cytoskeletal and motor structures such as microtubules, actin network, 
kinesins, and myo1C (90, 97-101).  In addition to the trafficking of GLUT4 
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towards the plasma membrane, insulin also regulates the docking and fusion 
of GLUT4 with the plasma membrane via SNARE accessory proteins, Synip 
and Munc18 (92, 102, 103).  Thus, insulin stimulated PI3K signaling cascade 
regulates GLUT4 translocation, docking and fusion to the plasma membrane, 
and the regulation of these processes by insulin occurs at multiple steps (93).  
Although, there are some reports of a PI3K independent pathway involved in 
glucose transport, the PI3K independent pathway is still controversial (99, 
104). 
 
Regulation of glycogenesis 
Evidences show that the insulin mediated PI3K signaling cascade induces 
glycogenesis in muscle and liver.  Glycogenesis is the process of glycogen 
synthesis mediated by the enzyme glycogen synthase (GS), that is 
responsible for the elongation of a glycogen chain by incorporating uridine 
5’diphosphoglucose derived from glucose-6-phosphate (105).  GS is 
phosphorylated and inhibited by the kinases such as PKA or glycogen 
synthase kinase (GSK).  Studies have shown that insulin stimulation 
phosphorylates and inhibits GSK, and activates protein phosphatase1 (PP1) 
via PI3K, and AKT2 (106-108).  It is thought that insulin mediated inhibition of 
GSK, and activation of PP1 result in decreased GS phosphorylation, and thus 
activation of GS (86, 109), thereby promoting glycogenesis. 
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Fig.1.1 Insulin signaling pathways. The binding of insulin to the insulin receptor (IR) 
initiates a phosphorylation cascade that begins from the IR.  Tyrosine phosphorylation of the 
IR recruits and phosphorylates insulin receptor substrate 1/2 (IRS1/2), which then bind and 
activate phosphatidylinositol 3-kinase (PI3K). PI3K phosphorylates PI (4,5) P2 to form PI 
(3,4,5)P3 that further phosphorylates downstream kinase 3-phosphoinositide-dependent 
protein kinase-1 (PDK1).  Phosphorylated PDK1 together with PI (3,4,5)P3 activates AKT that 
mediates most of the insulin effects.  AKT increases GLUT4 translocation directly as well as 
by inhibiting AS160, the inhibitor of GLUT4 translocation.  AKT activation promotes 
glycogenesis via inhibition of GSK and activation of PP1.  AKT also suppresses 
gluconeogenic gene expression by the inhibition of transcription factor FOXO1.  Similarly, 
insulin signaling via AKT activates phosphodiesterase enzyme (PDE) to decrease cAMP 
levels, thereby inhibiting lipolysis.  AKT promotes FA synthesis by activating Acetyl Co-
enzyme A Carboxylase 1 (ACC1), and inhibits FA oxidation by activating Acetyl Co-enzyme A 
Carboxylase 2 (ACC2).  The activation of IR by insulin also activates IRS1/2 to recruit GRB2 
and SOS, thereby activating Ras/MEK1/2/ERK1/2 to promote cell growth, proliferation, and 
differentiation. 
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Regulation of gluconeogenesis 
An important contributor to glucose homeostasis is the insulin-mediated 
regulation of gluconeogensis.  Gluconeogenesis is the process by which liver 
synthesizes glucose from lactate, glycerol, and amino acids to maintain the 
serum glucose levels during prolonged fasting.  It is, however, critical to inhibit 
this process of de novo glucose synthesis in the fed state in order to avoid 
glucose overload in serum, and this important function of inhibiting 
gluconeogensis after feeding is mediated by insulin.  Prior studies have 
suggested that insulin signals via PI3K/AKT2 pathway to phosphorylate and 
inhibits FOXO1, and PPARγ co-activator 1α (PGC1α), which are the 
transcription factors responsible for the expression of phosphoenolpyruvate 
carboxykinase (PEPCK), the rate-limiting enzyme in gluconeogenesis, and 
glucose-6-phosphatase (G6Pase) (110-113).  In addition to FOXO1 and 
PGC1α, insulin has also been shown to inhibit CREB binding protein (CBP), a 
co-activator of cAMP response element binding (CREB), and a transcription 
factor inducing gluconeogenic gene expression (114).  These studies show 
that insulin negatively regulates the process of gluconeogenesis in the liver by 
suppressing the expression of gluconeogenic genes. 
 
Regulation of Lipid Metabolism 
The regulation of lipid metabolism by insulin is mainly through the effect of 
insulin in adipocytes to promote lipid storage and inhibit lipolysis.  Prior 
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studies suggest that insulin increases storage of lipid in adipocytes in the form 
of triglycerides by promoting fatty acid reesterification, and triglyceride 
synthesis, as well as inhibiting fatty acid transport into mitochondria for α-
oxidation (86).  The fatty acid synthesis has been shown to be promoted by 
insulin-mediated activation of acetyl-coenzyme A carboxylase 1 (ACC1) 
whereas fatty acid oxidation is inhibited by insulin-mediated activation of 
acetyl-coenzyme A carboxylase 2 (ACC2) (115), thus giving the net result of 
fatty acid storage in adipocytes.  In addition, insulin has also been shown to 
induce the activity of sterol regulatory element binding proteins-1c (SREBP-
1c), a transcription factor involved in the expression of numerous enzymes 
involved in fatty acid and triglyceride synthesis, such as fatty acid synthase 
(FAS), steroyl-coenzyme A desaturase 1 (SCD1), acetyl-coenzyme A 
carboxylase (ACC), and glycerol-3-phosphate-1-acyltransferase (GPAT) 
(116).  Insulin not only promotes fat storage, but it also inhibits lipolysis in 
adipocytes.  Lipolysis in adipocytes is mediated through the activation of PKA 
by increased intracellular cAMP (discussed in detail in later sections).  
Previous studies have shown that insulin decreases intracellular cAMP by 
activating phosphodiesterase (PDE), an enzyme that converts cAMP to AMP, 
and thus inhibits lipolysis (117, 118). 
 
 
 
  22 
Regulation of cell growth and differentiation 
A different function of insulin compared to glucose and lipid homeostasis is 
the regulation of cell growth and differentiation (6, 119).  It involves increases 
in protein synthesis, and the activation of transcription factors required for cell 
proliferation and differentiation (120-126).  Evidences show that, insulin 
activates the transcription factors involved in cell proliferation and 
differentiation by stimulating the IR to recruit insulin receptor substrates, IRS 
and Grb2, which in turn bind to adaptor proteins, SHP2 and SOS, and 
together activate the serine kinase Ras (72, 86, 126, 127).  Activation of Ras 
starts the phosphorylation cascade at MEK that finally activates ERK where it 
translocates into the nucleus to further activate transcription factors such as 
Elk1, sap1a, and Fra1.  
 
In addition to the increase in transcription, insulin has also been shown to 
increase protein synthesis and decrease protein degradation (121-123).  The 
increase in protein synthesis is thought to be mediated via PI3K and mTOR 
activation.  This activation results in further activation of ATF4 which is 
responsible for regulating genes involved in amino acid biosynthesis and 
transporters (128).  It is hypothesized that the translation of proteins is 
increased due to mTOR stimulated ribosomal biosynthesis, and inhibition of 
the negative regulator of protein synthesis 4E-binding protein-1 (4EBP1) 
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(128-132).  Thus, the final outcome of increased protein synthesis after insulin 
stimulation allows cells to proliferate and differentiate. 
 
Insulin, therefore, regulates a constellation of cellular functions mainly through 
the PI3K/AKT pathway or the Ras/MEK pathway, and there is cross-talk 
between these two pathways at multiple levels.  Given the several important 
regulatory functions of insulin, it is predictable that any altercation in insulin 
signaling pathways resulting in insulin resistance will have a profound effect 
on whole body homeostasis.  Thus, it is of the utmost importance to 
understand the biology of not only insulin signaling, but also insulin 
resistance. 
 
Insulin Resistance 
Insulin resistance involves a disturbance of the insulin signaling cascade and 
its resultant inability to lower blood glucose to a normal level of 4-7 mM.  The 
persistent increase in blood glucose level above 7mM is the result of 
derangements in multiple physiological processes regulated by insulin such 
as glucose uptake in muscle and fat cells, suppression of gluconeogenesis in 
the liver, and promotion of glycogenesis in the liver and muscle.  Though a 
thorough knowledge of all the perturbations that lead to insulin resistance has 
yet to be achieved, the vast amount of studies in past years have identified 
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several molecular mechanisms and mediators that contribute to the 
development of insulin resistance. 
 
Molecular mechanisms of insulin resistance 
The molecular mechanisms of insulin resistance includes defects at multiple 
levels of the insulin signaling cascade including decreases in the IR 
concentration, or defects in the IR kinase activity, decreases in IRS and PI3K 
concentration and phosphorylation, decline in GLUT4 concentration and 
translocation, and faulty intracellular enzymes and transcription factors (72, 
86). 
 
The IR is critical for the initiation of signaling cascade, and any defect in its 
activity may be due to genetic mutations or acquired changes in its 
phosphorylation state.  The IR mutation, albeit rare, has been reported to 
cause insulin resistance of variable severity depending upon the ability of IR 
to hybridize with IGF-1 or other receptors (86).  
 
Despite the presence of normal IR, modifications of the phosphorylation state 
of the IR to serine phosphorylation instead of tyrosine phosphorylation can 
down regulate insulin signaling. The serine phosphorylation of IR has been 
shown to decrease insulin signaling by inhibiting tyrosine phosphorylation, 
and  promoting  the  association  with  14-3-3  proteins  (133, 134).   Similarly,  
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Fig.1.2 Mechanisms of Insulin Resistance. Insulin resistance may result from the 
decreased expression of Insulin receptor (IR) or mutations in IR.  Insulin resistance may also 
result from the disruption of phosphorylation cascade from serine phosphorylation instead of 
tyrosine phosphorylation of IR and insulin receptor substrate (IRS1/2).  The serine 
phosphorylation of IR and IRS1/2 are mediated by a number of kinases such as c-jun N-
terminal kinase (JNK1/2), Ikappa B kinase (IKKβ), protein kinase Cθ (PKCθ), and protein 
kinase Cε (PKCε).  The kinases JNK1/2 and IKKβ also decrease the expression of glucose 
transporter 4 (GLUT4), lipogenic genes, and increase the expression of inflammatory genes, 
thereby contributing to insulin resistance.  
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serine phosphorylation in place of tyrosine phosphorylation of IRS can also 
lead to diminished insulin signaling.  This process involves a number of 
kinases such as c-jun N-terminal kinase (JNK), PI3K, GSK-3, AKT, mTOR, 
protein kinase C (PKC), and IKappa kinase B (IKKB) (72, 135, 136).  
Alterations of these kinases in vivo have been shown to modify insulin 
sensitivity.  For example, in rodents, overexpression of IKKB in the liver leads 
to insulin resistance in liver and muscle whereas IKKB deletion confers 
protection against diet-induced hepatic insulin resistance (137).  In contrast to 
the kinases, IRS function can also be inhibited by the action of phosphatases 
that dephosphorylate IRS or IR as well.  One of the phosphatases protein 
tyrosine phosphatase 1 B (PTB1B), has been speculated to inhibit insulin 
signaling as demonstrated by mice deficient in PTB1B.  Mice deficient of 
PTB1B are more insulin sensitive, and are resistant to diet-induced obesity 
(138).  Besides kinases and phosphatases that modulate IRS 
phosphorylation, IRS signaling can also be inhibited by degradation of IRS 
induced by binding of suppressor of cytokine signaling 1 and 3 (SOCS1 and 
SOCS3) to IRS (139).  
 
The irregularities in the effectors downstream of the IR and IRS can also fuel 
insulin resistance. For example, absence of AKT2 in mice has been shown to 
cause insulin resistance in the liver and muscle (140). Similarly, adipose 
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tissue and muscle specific GLUT4 knockout mice also have impaired glucose 
tolerance, and insulin resistance (141, 142). 
 
Mediators of Insulin Resistance 
Apart from probing the molecular aspects of insulin resistance, a lot of effort 
has been made on exploring the mediators of insulin resistance.  Unraveling 
these mediators would assist to understand how molecular derangements of 
insulin signaling develop from the harbingers of insulin resistance, especially 
over-nutrition and obesity.    
 
Obesity is the increase in body weight particularly due to the accumulation of 
body fat that results from an imbalance between calorie intake and energy 
expenditure. Although obesity awareness is increasing currently, obesity has 
been recognized to be more than a progression of physiological storage of 
energy, and has been categorized as a chronic disease since National 
Institutes of Health Consensus Conference in 1985 (143).  Furthermore, in 
1986, the Framingham Heart Study has shown the risk of death within 26 yr 
increases by 1% for each extra pound added to the weight of an individual 
between 30 to 42 yr of age, and the risk increases to 2% for each pound 
gained between 50 to 62 years of age (144).  In fact, future life expectancy, 
the predictor of health and health care, may decline for the first time due to 
the escalation of obesity incidence (145).  Although obesity is associated with 
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numerous chronic diseases such as osteoarthritis and fatty liver disease, the 
most common diseases correlating with obesity are cardiovascular diseases 
and insulin resistance, which constitute the metabolic syndrome.  Studies 
trying to elucidate the progression of obesity to insulin resistance, and 
metabolic syndrome have identified mediators such as adipokines, 
inflammatory cytokines, lipids, and FFAs that emphasizes the importance of 
adipose tissue in maintaining the whole body glucose metabolism. 
 
Adipokines are the hormones secreted by the adipose tissue (discussed in 
detail in “Adipose tissue as an endocrine organ” section).  In obesity, the 
balance between adipokines conferring insulin sensitivity and insulin 
resistance is disturbed. It is observed that secretion of adipokines such as 
adiponectin that promote insulin sensitivity, are decreased in obese 
individuals whereas adipokines contributing to insulin resistance such as 
resistin, RBP4, and inflammatory cytokines such as TNF-α and IL-6 are 
increased, thus creating a pro-insulin-resistant environment. 
 
Inflammatory cytokines 
Prior evidences have shown increase in the circulating levels of inflammatory 
cytokines, and macrophage infiltration in the adipose tissue in obesity, 
suggesting the association of obesity with chronic low-grade inflammation 
(146).  Although the etiology of inflammation in obesity is not known, the role 
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of inflammatory cells, particularly macrophages, has emerged after the 
detection of resident macrophages in the adipose tissue (147, 148).  More 
macrophages are present in adipose tissue in obese individuals probably due 
to increased expression of MCP-1 by hypertrophied adipocytes (149).  These 
macrophages fuse to form a ring-like structure around dead adipocytes 
known as “crown-like structure’’ in order to clear dead cells (150).  These 
“crown-like structures” are considerably increased in obesity suggesting 
increased adipocyte necrosis in obesity (151).  The causes of adipocyte 
necrosis may be several, and hypoxia due to expansion of adipose tissue with 
reduced blood supply is one of the proposed causes (152, 153). 
Nevertheless, the activation of infiltrated macrophages in adipose tissue, 
and/or hypoxia leads to the increased expression of inflammatory cytokines 
such as TNF-α and IL6 (154-157). 
 
TNF-α 
Among the inflammatory cytokines that are elevated in obesity, TNF-α has 
been extensively studied, and its association with obesity induced insulin 
resistance has been well established.  The levels of TNF-α in the serum has 
been reported to correlate with body weight (158), and is increased in obesity.  
Similarly, increased expression of TNF-α has been detected in adipose tissue 
from obese diabetic rodents, and has been hypothesized to mediate insulin 
resistance (159).  Consistently, circulating TNF-α, and local gene expression 
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of TNF-α in adipose tissue are increased in obese humans also (160), and 
acute infusion of TNF-α in healthy humans has been shown to increase 
insulin resistance (161).  Furthermore, inhibition of TNF-α function by genetic 
deletion of TNF-α or TNF-α receptor (TNFR) has been shown to prevent 
obesity induced insulin resistance (162-164).  However, neutralization of TNF-
α with TNF-α antibody improves insulin sensitivity only in rodents, but not in 
humans (159, 165). Despite the discrepancy of the effect of TNF-α antibody 
on insulin sensitivity in rodents and humans, evidences indicating the role of 
TNF-α in obesity related insulin resistance are substantial. 
 
Although the adipocyte expression of TNF-α is increased in obesity, a more 
important source of TNF-α from the fat tissue is considered to come from the 
cells in the stromal vascular fraction, and infiltrated macrophages (147, 148, 
166-170).  The expressed TNF-α protein exists as a 26 kDa transmembrane 
monomer, and a smaller 17 kDa soluble TNF-α formed after proteolytic 
cleavage of membrane TNF-α.  Both membrane bound and soluble form of 
TNF-α can mediate the metabolic effects of TNF-α via stimulation of the 
TNFR (166).  Between the two TNFRs, expressed ubiquitously, TNF-α 
receptor-1 (TNFR1) mediates most of the TNF-α actions in adipocytes.  It has 
been shown that deletion of TNFR1 improves insulin sensitivity in vitro and in 
vivo (171-173).  The activation of TNFR initiates several cellular signals that 
may contribute to the development of insulin resistance. 
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The binding of TNF-α to TNFR1 activates several pathways to activate 
kinases such as JNK, extracellular signal-related kinase (ERK), PKC, and 
IKKB, which inhibit insulin-stimulated tyrosine phosphorylation of both the IR 
and IRS, thus impairing insulin function.  TNF-α signaling in adipocytes also 
suppresses a number of genes required for insulin signaling such as IR, IRS 
and GLUT4.  In addition to these genes, TNF-α also suppresses lipogenic 
genes and adiponectin probably via suppression of the master transcription 
factor PPARγ.  Altogether, the effect of TNF-α on transcription in adipocytes 
results in decreased adipocyte differentiation and a decrease in TG 
accumulation. (See reference (135, 166) for more detailed review).  
 
Lipolysis in Adipocytes 
In the low-grade inflammatory state of obestiy, TNF-α is hypothesized to be 
the main mediator of lipolysis.  Lipolysis is a process by which various lipases 
hydrolyze TG in lipid droplets to glycerol and FFAs.  One of the proposed 
mechanisms by which TNF-α increases lipolysis in adipocytes is the 
suppression of perilipin that coats the lipid droplets to protect against lipases 
(174).  The suppressive effect of TNF-α on perilipin may be via PPARγ, which 
drives the transcription of perilipin in adipocytes (16).  TNF-α has also been 
shown to reduce the level of Gi protein with a function of inhibiting lipolysis 
(175).  Another inhibitor of lipolysis is PDE, and TNF-α has been implicated in 
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Fig. 1.3 TNF-α  mediated insulin resistance. TNF-α acts via the TNF-α receptor (TNFR1) to 
activate downstream kinases such as c-jun N-terminal kinase (JNK1/2), IKappa B kinase 
(IKKβ), and protein kinase C (PKC θ,ε). These kinases phosphorylate insulin receptor (IR) 
and insulin receptor substrate (IRS1/2) at serine residues that disrupts the insulin signaling 
cascade.  JNK1/2 and IKKβ also suppress the expression of IR and IRS via NFκB and AP-1 
transcription factors.  NFκB and AP-1 also suppress PPARγ, thereby decreasing the 
expression of lipogenic genes, adiponectin and glucose transporter (GLUT4).  TNF-α also 
suppresses the expression and activation of phosphodiesterase (PDE).  The inhibition of 
PDE together with suppressed lipogenic genes increases lipolysis, thus releasing free fatty 
acids (FFA) into the circulation. Elevated FFA and decreased adiponectin both contribute to 
the development of systemic insulin resistance. 
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the decrease in the expression and activation of PDE (176).  In addition to 
these, TNF-α may also mediate lipolysis by disruption of the insulin signaling 
cascade, and inhibition of the anti-lipolytic actions of insulin.  All of the above 
effects of TNF-α lead to the increases in lipolysis in adipocytes.  Despite the 
discovery of various molecular mechanisms of TNF-α mediated lipolysis, the 
complete understanding of all of the mechanisms of multifunctional TNF-α 
has remained elusive. 
 
The increase in adipocyte lipolysis in obesity can also be due to the increased 
adipocyte size.  Previous studies have reported that the rate of lipolysis 
correlates with the size of adipocytes, and the level of pro-lipolytic signaling 
molecule, cAMP, is higher in larger adipocytes  (177, 178).  Moreover, it has 
also been shown that hypertrophied adipocytes have decreased insulin 
sensitivity, and thus have decreased insulin-mediated anti lipolytic effect 
(179). 
 
Unlike the hypertrophy of adipocytes and the effects of TNF-α to mediate 
lipolysis in obesity, the physiologic stimuli for lipolysis are catecholamines: 
adrenaline and nor adrenaline.  These hormones are released during fasting 
and bind to β adrenergic receptors that are coupled to G proteins.  The 
activated G proteins further activate adenylate cylase, an enzyme that 
converts ATP to cAMP, thus increasing intracellular cAMP levels.  The 
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elevated cAMP ultimately activates cAMP dependent protein kinase, PKA 
(135, 177, 180, 181).  Activation of PKA then phosphorylates perilipin, and 
hormone-sensitive lipase (HSL), which can then interact and enhance 
lipolysis (180, 182-186).  HSL is a lipase that preferentially hydrolyzes 
diacylglycerols (187), and is required for normal adipose tissue function.  It 
has been observed that HSL depleted mice have reduced adipose tissue, and 
a decreased lipolytic response to catecholamines (188, 189).  Another lipase, 
adipocyte triglyceride lipase (ATGL), has also been demonstrated to be 
required to mediate lipolysis in response to catecholamines (184, 190-192), 
and catalyzes the initial step in TG hydrolysis (192, 193).  Similar to HSL 
deficient mice, ATGL deficient mice have also been shown to exhibit defective 
lipolysis after catecholamine treatment (190). 
 
Irrespective of the stimuli for lipolysis, the TG hydrolysis leads to the release 
of glycerol and FFAs that efflux from adipocytes into the circulation.  These 
released FFAs provide fuel to tissues such as muscle and liver during fasting 
when serum glucose levels are low. However, with chronic and excessive 
lipolysis, serum FFA levels are elevated causing lipotoxicity, and thereby 
insulin resistance.  The mechanism of FFA-induced insulin resistance has 
been hypothesized to be caused by the inhibition of glucose uptake, glycogen 
synthesis and glucose oxidation as well as by increasing hepatic glucose 
output (86, 194).  Increased FFA is also associated with diminished insulin  
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Fig. 1.4 Regulation of Lipolysis in adipocytes. Catecholamines activate adenylate cyclase 
(AC) via β adrenergic receptor (β AR).  Activated AC converts ATP to cAMP that further 
activates cAMP activated protein kinase A (PKA).  Once activated PKA phoshorylates 
perilipin (PLIN), which acts as a docking site for phosphorylated hormone sensitive lipase 
(HSL).  The phosphorylation of perilipin releases CGI-58 that then interactes with ATGL 
(Adipocyte Triglyceride Lipase) and promotes ATGL lipase activity  The action of HSL and 
ATGL on triglycerides (TG) releases glycerol and free fatty acids (FFA).   TNF-α decreases 
the expression of PLIN that removes the protective covering of lipid droplets, and inhibits 
phophodiesterase (PDE) to increase cAMP, thus promoting lipolysis. Insulin activates insulin 
receptor (IR), and then activates PDE, which decreases cAMP levels, thereby inhibits 
lipolysis. 
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stimulated IRS-1 phosphorylation and PI3K activity (195).  On the other hand, 
higher levels of circulating FFAs also promote accumulation of TG and fatty 
acid metabolites such as diacylglycerol (DAG), fatty acyl CoA and ceramide 
accumulation in the liver and muscle tissue.  It has been observed that 
ectopic accumulation of TG in muscle correlates with insulin resistance in 
patients with obesity and diabetes (196).  Despite the limited knowledge of 
how FFAs mediate insulin resistance, it is apparent that FFA metabolism and 
regulation have an impact on maintaining whole body insulin sensitivity. 
 
Lipid droplets and associated proteins 
To prevent the deleterious effects of elevated circulating FFAs, these are 
sequestered and stored in the form of TG in lipid droplets in adipocytes.  The 
lipid droplets are now considered as a dynamic organelle rather than simply a 
lipid storage unit.  The lipid droplet consists of a central core of neutral lipids, 
mainly TGs and some choleresterol esters, surrounded by a monolayer of 
phosholipids.  Although, the formation of lipid droplets is still under 
investigation, the current theory suggests that TGs are synthesized in the 
endoplasmic reticulum (ER) through a process of enzymatic esterification.  
This theory is supported by studies that show numerous enzymes involved in 
TG biosynthesis such as acyl–CoA synthetase (ACS), glycerol-phoshate 
acyltransferase (GPAT), acylglycerol-phosphate acyltransferase (AGPAT), 
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Fig 1.5 Role of the Adipocyte in the regulation of free fatty acids (FFAs).  The circulating 
glucose is taken up by adipocytes where the glucose either undergoes glycolysis in the 
cytosol, and then oxidative phosphorylation in the mitochondria or undergoes triglyceride 
(TG) synthesis to be stored in lipid droplets.  TG in lipid droplets can undergo lipolysis to 
release FFAs during fasting.  Increased circulating FFAs during hyperphagia can enter 
adipocytes either to be stored in lipid droplets or to be β oxidized in mitochondria.  In obesity, 
the balance between lipolysis and storage is disturbed so that more FFAs are released.  
These FFAs efflux into the circulation, and mediate insulin resistance in other tissues such as 
the liver and muscle tissue. 
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and diacylglycerol acyltransferase (DGAT) fractionate with the ER, and show 
that these enzymes reside in the ER (116, 197-201).  In addition, TG droplets 
are surrounded by or even seen continuous with the ER suggesting the ER as 
a site of origin of lipid droplets (202-205).  It is speculated that the newly 
synthesized triacylglycerols accumulate to form a disc in the interior of the ER 
bilayer.  Increase in the size of the lipid disc leads to the budding off of the 
lipid disc along with the monolayer of the ER membrane.  However, the 
phospholipid monolayer on the surface of the lipid droplet is distinct from the 
phospholipid layer of the ER suggesting that the budding of lipid droplets from 
the ER may occurs at the specialized subdomains of the ER, or may be a 
completely different process (206)  The growth of lipid droplet size is also not 
fully understood.  It is theorized that the emerging small lipid droplets bud off 
from the ER, and are directed towards existing cytosolic lipid droplets where 
the smaller droplets fuse with the existing larger droplets, or transfer TG to 
the larger droplets (197).  It is also possible that the existing lipid droplets 
grow in size by synthesizing TGs themselves because the enzymes involved 
in TG synthesis are present in these lipid droplets as well. 
 
The lipid droplets consist of a core of hydrophobic TGs surrounded by a 
phospholipid monolayer, and proteins.  The proteins surrounding the lipid 
droplets are different depending upon the cell type, metabolic condition, and 
even different between lipid droplets within a cell (207). Previous studies have 
  39 
identified several proteins associated with lipid droplets such as perilipin, 
adipocyte related protein (ADRP), tail-interacting protein of 47 kDa (TIP47), 
S3-12, OXPAT, Cell Death-inducing DFF45-like effector proteins (CIDE 
proteins), and various lipases.  The lipases such as HSL and ATGL may 
associate with the lipid droplet surface in the lipolytically active state as 
described earlier in “Lipolysis in Adipocytes” section.  The other lipid droplet 
proteins were grouped together as “PAT” family of proteins after the discovery 
of the first three members: perilipin, ADRP, and TIP47.  They share common 
domains that are thought to be responsible for lipid targeting and anchoring.  
These proteins are further sorted into two groups: Exchangeable TG 
associated PAT proteins (EPATs) and Constitutively TG associated PAT 
proteins (CPATs).  EPATs consist of TIP47, S3-12 and OXPAT, and are 
constitutively present in the cytosol, and are thought to coat lipid droplets as 
they emerge from the ER.  On the other hand, CPATs are found only bound 
to the lipid droplets because the unbound free CPATs are rapidly degraded.  
Perilipin and ADRP are two proteins grouped as CPATs (197).   
 
Perilipin 
Perilipin is the most extensively studied lipid droplet associated protein.  Of 
the three isoforms of perilipin: perilipin A, B, and C, perilipin A is the most 
abundant, and thus the most commonly studied lipid droplet protein.  Not only 
is perilipin highly expressed in adipocytes, it is also considered a marker of 
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adipocyte differentiation.  In addition, the expression of perilipin in adipocytes 
is under the control of PPARγ, the adipogenic transcription factor (16).  Once 
expressed and targeted to the lipid droplet, perilipin is very stable with a half-
life of 40h (208), however, the unbound perilipin is rapidly degraded. Two 
groups studying the mechanism of perilipin degradation showed different 
results: Xu et. al. indicated proteasomal degradation, while Kovsan et. al. 
suggested lysosomal degradation (209-211). 
 
Perilipin surrounding the lipid droplets is postulated to form a protective coat, 
and decrease the rate of TG hydrolysis (212-214).  Loss of perilipin under 
conditions such as TNF-α treatment promotes lipolysis (174).  In addition, in 
vivo rodent models lacking perilipin also have increased basal lipolysis (215, 
216).  Interestingly, transgenic mice overexpressing perilipin in the adipose 
tissue exhibit protection against diet-induced obesity, despite the propensity 
of perilipin to store fat (217).  However, the overexpression of perilipin in 
adipocytes protects lipid droplets from lipolysis stimulated by TNF-α, but not 
by catecholamines (174). In fact, previous studies have shown that the 
phosphorylation of perilipin by catecholamines is a necessary event for 
catecholamine-mediated lipolysis, and is further supported by the data from 
the perilipin null mice that have attenuated stimulated lipolysis (215, 216).  
The phosphorylation of perilipin has been avidly researched, and has been 
shown to be involved in multiple aspects of lipid metabolism.  For example, 
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phosphorylation of perilipin at Ser517 is essential for the activation of ATGL 
activity, and lipolysis (218).  On the other hand, perilipin promotes HSL-
mediated hydrolysis via both phosphorylation dependent, and independent 
mechanisms (219, 220).  Moreover, phosphorylation of perilipin at Ser492 is 
responsible for lipid droplet fragmentation, and dispersion after catecholamine 
stimulation.  In addition, perilipin also controls lipid metabolism by interacting 
with other proteins such as CGI-58, an activator of ATGL (221, 222).  The 
importance of perilipin in metabolism is exemplified by the association of 
increased risk of diabetes with several SNPs detected in the perilipin gene 
(207).  
 
ADRP 
ADRP also known as adipophilin, like perilipin, has also been found to be 
constitutively bound to lipid droplets.  In the free form ADRP is rapidly 
ubiquitinated to be degraded via the proteasome (223).  ADRP is expressed 
early during adipogenesis, but its expression declines during maturation and 
is ultimately replaced by perilipin in mature adipocytes (197).  In addition to 
adipocytes, ADRP is also found in other cells that accumulate lipid, e.g. 
macrophages (224). Although the ADRP-null mice has normal adipogenesis 
and adipose tissue, the TG content is reduced in hepatocytes, and these mice 
are resistant to hepatic steatosis induced by high fat feeding (225).  
Conversly, the overexpression of ADRP promotes TG accumulation in 
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different types of cells like fibroblasts, COS and hepatocytes in culture (226-
228).  It has been shown that ADRP expression is increased upon 
isoproterenol treatment of adipocytes via a PKA independent mechanism 
(229).  Although ADRP is post-translationally modified, the implication of such 
modification has not been uncovered.   
 
TIP47, S3-12, OXPAT 
TIP47 (PP17/M6PBP), S3-12 and OXPAT (MLDP, LSDP5) are stable lipid 
droplet proteins that can shuttle between lipid droplets and the cystosol.  TIP 
47 is ubiquitously expressed, whereas S3-12 is preferentially present in 
adipocytes, and OXPAT is primarily expressed in the heart, skeletal muscle 
and liver.  Although these proteins are not studied in detail yet, it has been 
shown that these proteins can be associated with lipid droplets, and promote 
TG accumulation (197, 207). 
 
CIDE Proteins 
The newest proteins to emerge in the field of lipid droplet proteins are CIDE 
proteins.  CIDE proteins have three isoforms: CIDEA, CIDEB, and CIDEC 
(FSP27).  These proteins have domains homologous to DNA fragmentation 
factor 45 (DFF45) (230), but more importantly have domains homologous to 
perilipin, and are thought to be responsible for lipid droplet targeting, 
anchoring, and shielding (231).  Recently, our lab has shown both CIDEA and 
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CIDEC are targeted to lipid droplets (232, 233), and subsequently has 
initiated intensive interest in these proteins.  Although some studies have 
shown the effect of CIDE proteins in apoptosis by virtue of its DFF45 domain, 
high expression of CIDEC in adipocytes does not cause cell death (234, 235), 
and increasing evidence supports their more important role in the lipid 
metabolism. 
 
CIDEA is highly expressed in the mouse BAT, and its depletion in mice leads 
to protection against diet-induced obesity and insulin resistance.  Two 
different studies by the same group published that CIDEA binds and 
represses UCP1 in the mitochondria (236), and then later published that 
CIDEA is localized to the ER, and suppresses AMP-activated protein kinase 
(AMPK) activity (237).  However, later studies have confirmed the localization 
of CIDEA in lipid droplets instead of mitochondria (231).  Similar to other lipid 
droplet proteins, the expression of CIDEA is controlled by PPARγ and PPARα 
(17).  CIDEA is rapidly ubiquitinated, and degraded via the proteasome (238).  
In contrast to rodents, CIDEA is highly expressed in the human WAT.  It has 
been shown that CIDEA expression is down regulated in obese humans, and 
increases after weight loss.  CIDEA expression is also observed to decrease 
with TNFα treatment, and the decrease in CIDEA is associated with 
increased lipolysis (239, 240).  In addition, the expression of CIDEA is 
decreased in obese insulin resistant individuals compared to obese insulin 
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sensitive ones (231).  Taken together, these data suggest a role for CIDEA in 
lipid metabolism, and is further supported by the detection of CIDEA V115F 
polymorphism association with obesity in Swedish and Japanese population 
(241, 242). 
 
CIDEB is mainly expressed in the hepatocytes.  Studies with CIDEB null mice 
have shown decreased lipogenesis in hepatocytes, and resistance to obesity 
in response to a high fat diet.  These mice also have increased insulin 
sensitivity, and hepatic fatty acid oxidation (243).  CIDEB is reported to 
interact with apolipoprotein B to promote the formation of TG-enriched very 
low-density lipoproteins (VLDL) (244).  In addition, CIDEB has also been 
shown to be involved in cholesterol metabolism in the liver (245). 
 
CIDEC, also known as Fat Specific Protien 27 (FSP27) in mice, is 
preferentially expressed in white adipocytes.  The expression of FSP27 is 
under the transcriptional control of PPARγ2 (246).  The expression of FSP27 
increases after treatment with the PPARγ agonist, rosiglitazone, (a common 
medication used with type 2 diabetic patients) (247).  FSP27 is targeted to 
lipid droplets via its CIDE C domain (248), and promotes lipid accumulation, 
and unilocular lipid droplet formation in vitro and in vivo.  Consistently, 
depletion of FSP27 in adipocytes in culture, or in mouse models leads to lipid 
droplet fragmentation, and lipolysis (233, 234).  It is proposed that FSP27 
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enhances lipid accumulation by decreasing β oxidation of fatty acids (249).  It 
is also observed that FSP27-null mice have increased mitochondrial activity, 
and the white adipocytes become more like brown adipocytes (234, 250).  In 
addition, FSP27 depleted mice are resistant to diet-induced obesity, and 
insulin resistance.  The increased insulin sensitivity in FSP27 deficient mice 
has been reported to be associated with an increase in IRS-1 and AKT 
phosphorylation, and an increase in GLUT4 expression in adipose tissue 
(250).  However, a CIDEC homozygous nonsense mutation in human that is 
analogous to FSP27 knock-out mice is associated with lipodystrophy and 
insulin resistance where as FSP27 knock-out mice are insulin sensitive (251).  
It can be argued that FSP27 null mice are lacking FSP27 completely, 
whereas the mutated CIDEC in humans are still expressed but are unable to 
target to lipid droplets.  Perhaps the presence of mutated FSP27 does not 
allow the increase in β-oxidation, and IRS-1/AKT phosphorylation that may 
contribute to improved insulin sensitivity in mouse models.  Though, human 
and mouse models are different in the FSP27 knock-out aspect, both human 
and mouse models have decreased FSP27 expression associated with 
obesity.  Both ob/ob and high-fat diet induced obese mice have decreased 
expression of FSP27 as the obesity progesses and decreased insulin 
sensitivity ensues.  In case of obese humans, CIDEC protein is observed to 
be down regulated in the insulin resistant obese patients compared to the 
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insulin sensitive obese patients (231).  Taken together, these data suggest 
that FSP27/CIDEC has an important role in lipid metabolism. 
 
Specific Aims: 
Previous studies have shown the association of elevated circulating FFAs 
with obesity and insulin resistance (252).  The increase in circulating FFAs 
has been speculated to contribute to insulin resistance in humans and mice 
whereas decrease in circulating FFAs by an antilipolytic drug acipimox 
improves insulin sensitivity (253-255).  Studies have demonstrated that the 
higher circulating FFA levels also promote ectopic accumulation of TG in the 
muscle, that may contribute to insulin resistance (135).  These FFAs in 
circulation may come from ingested food as well as from the adipose tissue 
via lipolysis.  Lipolysis can be stimulated by catecholamines during fasting, or 
by cytokines such as TNF-α in the state of chronic inflammation and obesity 
(180, 256).  On the other hand, these FFAs can be sequestered and stored 
as TG in lipid droplets in adipocytes.  Thus, the functional integrity of adipose 
tissue is essential, perhaps to prevent the adverse effects of FFAs.  The 
deficiency of adipose tissue in both rodents and humans has been shown to 
be related to the higher circulating levels of FFAs, and insulin resistance (20-
23). 
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In adipocytes, the balance between lipogenesis in the fed state, and lipolysis 
in the fasting state is finely controlled by several regulators including proteins 
associated with lipid droplets.  One of the lipid droplet proteins shown to 
promote lipid accumulation in vitro and in vivo is FSP27.  FSP27 is a novel 
lipid-droplet associated protein.  FSP27 is observed to be decreased in the 
obese insulin resistant individuals compared to the obese insulin sensitive 
ones (231).  In addition to this, FSP27 mutation has been reported in humans 
with partial lipodystrophy and insulin resistance (251).  In contrast to human 
data, it is the absence of FSP27 that promotes insulin sensitivity in rodents 
(234).  On the other hand, FSP27 depletion leads to formation of smaller lipid 
droplets, and lipolysis in both humans and rodents (233, 235, 249, 257).  
Although previous studies have suggested the role of FSP27 in lipid 
metabolism, and insulin sensitivity, not much is known about the regulation of 
FSP27, and the effect of FSP27 alteration in lipid metabolism.  Understanding 
the regulation of FSP27 in normal and obese conditions, and its role in lipid 
metabolism will provide new insights to the present knowledge of lipid 
metabolism.  Therefore, this study explores the role and regulation of FSP27 
in the basal state as well as during lipolysis in adipocytes. 
 
The specific aims of this study are: 
1. To determine how FSP27 is regulated in the basal condition.  This 
study and a recently published study show that FSP27 has a half life of  
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Fig. 1.6:  Investigating the effect of TNF-α  and isoproterenol on FSP27 and its effect on 
lipolysis.  FSP27 has been shown to promote unilocular lipid droplet formation by 
decreasing lipolysis.  The work presented in this thesis investigates if there is an effect of 
lipolytic stimuli such as TNF-α and isoproterenol  on FSP27, and if there is an effect of such 
stimuli on FSP27 what is the implication of FSP27 regulation by these stimuli on overall 
lipolysis. 
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less than 15 min because it is rapidly ubiquitinated, and degraded via 
the proteasome (258). 
2. To test if TNF-α, the cytokine elevated in the obese state, has any 
effect on FSP27, and if the effect of TNF-α on FSP27 plays a role in 
the lipolysis mediated by TNF-α.  This study identifies the depletion of 
FSP27 by TNF-α as a novel mechanism of TNF-α mediated lipolysis. 
3. To examine if the physiological stimuli of lipolysis, catecholamine, 
regulates FSP27, and the role of catecholamine mediated regulation of 
FSP27 in stimulated lipolysis. This study shows catecholamines 
upregulates FSP27 by decreasing FSP27 ubiquitination, and 
degradation. These results are also consistent with a recently 
published study (258).  This study further shows the paradoxical 
increase of FSP27 after catecholamine stimulation may be due to a 
feedback mechanism to protect adipocytes from the potent lipolytic 
effect of catecholamines.  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Summary 
 
FSP27, a lipid droplet-associated protein, functions to suppress lipolysis and 
thereby enhance triglyceride accumulation in adipocytes (233, 234, 249).  Our 
result is consistent with the literature showing FSP27 is under the control of 
the transcription factor PPARγ, the master regulator of adipogenesis (246).  
FSP27 was recently found by us and others to be a remarkably short-lived 
protein, with a half-life of only 15 min, due to its rapid ubiquitination and 
degradation by the proteasome (258). 
  
As FSP27 has a rapid turnover in adipocytes, we tested the hypothesis that 
the regulation of FSP27 protein levels is a mode by which the lipolytic agents 
TNF-α, a cytokine, and isoproterenol, a β-adrenergic agonist, act to regulate 
FFA release from adipocytes.  Consistent with this concept, we report here 
that TNF-α markedly and rapidly decreases FSP27 mRNA and protein levels, 
and in parallel decreases lipid droplet size and increases glycerol release.  
Similar depletion of FSP27 using siRNA mimicked the action of TNF-α to 
enhance lipolysis, while prevention of the decrease in FSP27 protein by TNF-
α using adenovirus-directed expression of FSP27 blocks the effects of TNF-α 
on lipolysis and lipid droplets size.  Analysis of the time course during TNF-α 
treatment of cultured adipocytes revealed that the decrease in FSP27 protein 
levels precedes the decrease in lipid droplet size, which in turn is followed by 
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increased lipolysis.  As expected, the lipase, ATGL, is required for the 
increased lipolysis caused by either FSP27 depletion or TNF-α treatment.  
Together these data identify FSP27 as an important intermediate in the 
mechanism of TNF-α actions on two distinct processes of diminishing lipid 
droplet size, and stimulating lipolysis in cultured adipocytes.  
 
In contrast to the effect of TNF-α on FSP27, the much greater lipolytic action 
of isoproterenol is paradoxically associated with increases in cellular FSP27 
protein levels, and a delayed degradation rate corresponding to decreased 
ubiquitination.  These results are consistent with a recently published study 
(258).  The catecholamine-mediated increase in FSP27 abundance is 
mimicked by Forskolin or soluble 8-Bromo-cAMP treatment, and prevented by 
PKA inhibitor KT5720 or PKA depletion using siRNA.  Despite the necessity 
of PKA for isoproterenol-mediated stabilization of FSP27, PKA does not 
phosphorylate FSP27 suggesting an involvement of another protein or 
proteins in the stabilization of FSP27 in response to isoproterenol.  The 
results in this study also show that isoproterenol increases cellular FSP27 
levels despite blunted lipolysis in adipocytes transfected with ATGL siRNA, 
suggesting that lipolytic effect of catecholamines is not required for 
catecholamine mediated stabilization of FSP27.  Furthermore, adenovirus 
directed expression of FSP27 is able to protect against isoproterenol 
mediated lipid droplet size diminution.  This data indicates that depletion of 
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FSP27 plays a role in catecholamine-mediated lipid droplet dispersion.  
However, adenovirus directed expression of FSP27 does not protect against 
the catecholamine-stimulated lipolysis.  These results are consistent with my 
previous results suggesting lipolysis and lipid droplet dispersion are two 
separate processes, and also suggest that FSP27 depletion, unlike TNF-α, is 
not a mechanism of catecholamine-mediated lipolysis.  However, I 
hypothesize that the stabilization, and increase of FSP27 after isoproterenol 
treatment of adipocytes is a feedback mechanism to restrain the potent 
lipolytic effect of catecholamines because there is an increase in the rate of 
lipolysis in response to isoproterenol treatment when the isoproterenol-
mediated increase in FSP27 levels is prevented using siRNA.  
 
These studies show that modulation of the cellular levels of FSP27, a rapidly 
turned-over protein, is an important mechanism by which lipolytic stimuli 
regulate lipolysis in adipocytes.  The lipolytic cytokine, TNF-α, increases 
lipolysis in adipocytes by decreasing FSP27.  On the other hand, 
catecholamines increase cellular FSP27 by decreasing ubiquitination and 
degradation, thereby possibly restraining its own potent lipolytic effect. 
 
INTRODUCTION 
Storing excess energy for future use during starvation is critical for survival of 
mammals.  Such excess energy is stored in the form of TGs within lipid 
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droplets present most abundantly in adipocytes, which in turn are 
accumulated as depots such as subcutaneous and visceral adipose tissue in 
mice and humans.  TGs in lipid droplets are mobilized in starvation to release 
energy in the forms of glycerol and FFAs by lipase-catalyzed lipolysis, 
providing fuel to other cell types such as muscle and liver.  Previous work on 
formation of lipid droplets and regulation of lipolysis have elucidated the 
importance of lipid droplet associated proteins for these processes (256, 259).  
Based on shared sequence homology, one set of lipid droplet proteins is 
grouped as the PAT (Perilipin-Adipophilin-TIP47) family of proteins (197).  
PAT-related proteins are functionally conserved from mammals to lower 
organisms such as Drosophila and Dictyostelium (260).  In Drosophila, two 
PAT domain proteins are encoded by Lsdp1 and Lsd2 genes.  Loss-of-
function Lsd2 mutants in Drosophila are lean whereas overexpression of Lsd2 
causes obesity (261).  In mammals, PAT proteins can be divided into 
exchangeable TG-associated PAT proteins (EPATs) or constitutively TG-
associated PAT proteins (CPATs).  EPATs include TIP47, S3-12 and 
OXPAT/MLDP.  These are stably expressed in cytosol and bind nascent TAG 
droplets.  CPATs include perilipin and adipophilin, which are bound to neutral 
lipid droplets, and are rapidly degraded when dissociated from the lipid 
droplets (197).  Thus, expression of the different sets of lipid droplet proteins 
contributes to the finely tuned regulation of TG deposition in lipid droplets. 
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Lipolysis of TG into glycerol and FFAs is also controlled by various 
physiological stimuli such as β-adrenergic agonists in fasting, and TNF-α 
secreted by macrophages that infiltrate adipose tissues in obesity.  
Stimulation of β-adrenergic receptors by the catecholamines epinephrine, 
norepinephrine and isoproterenol activates adenylyl cyclase, increasing 
intracellular cAMP levels, and activating cAMP-dependent PKA.  This protein 
kinase catalyzes phosphorylation of HSL as well as perilipin, which can then 
interact and enhance lipolysis (180, 182-186).  TNF-α on the other hand 
decreases perilipin expression, which also leads to increased lipolysis, albeit 
with a longer time course and to a lesser extent than the effect of 
catecholamines.  Additionally, preventing the depletion of perilipin by TNF-α 
by expression of perilipin via an adenovirus vector has been shown to protect 
against TNF-α mediated lipolysis (174).  In addition, adipocytes from perilipin 
null mice display a higher basal lipolytic rate (215, 216).  These mice exhibit 
an attenuated lipolytic response to β-adrenergic stimulation, reinforcing the 
importance of perilipin in the mechanism of lipase action to enhance TG 
hydrolysis.  
 
Recently, our laboratory identified FSP27 as a highly expressed adipocyte 
protein that also associates with lipid droplets (233) and has a significant 
homology to domains in perilipin thought to be responsible for triglyceride 
shielding from lipases and for lipid droplet targeting and anchoring (231).  
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These findings have been confirmed and extended to show that FSP27 
expression is associated with increased lipid droplet size and triglyceride 
accumulation in adipose and non adipose cell-types (233-235, 249).  FSP27 
is a member of CIDE (Cell Death Inducing DFF45-like effector) family of 
proteins that have a common CIDE-N domain in the N-terminus and CIDE-C 
domain in the C-terminus  (230).  Thus, the human FSP27 is also denoted 
CIDEC.  FSP27 was first identified as an adipocyte-specific gene  (262) and 
later shown to have homology to 45kDa subunit of DNA fragmentation factor 
(230).  It is highly expressed in white adipose tissue in mice as well as 
humans, and has been shown to be upregulated during 3T3-L1 adipogenesis 
(235).  Despite having CIDE domains, FSP27 upregulation during 
adipogenesis does not lead to apoptosis (235).  Proteomic analysis of lipid 
droplet-associated proteins in adipocyte homogenates has also revealed 
FSP27 to be in the lipid droplet fraction (263).  Studies in both cultured cells 
and intact mice have confirmed that FSP27 depletion causes lipid droplet 
fragmentation in adipocytes (233, 234), suggesting it is necessary for 
formation of large unilocular lipid droplets of primary mouse and human 
adipocytes.  
 
Since siRNA-mediated depletion of FSP27 causes increased lipolysis of lipid 
droplet TGs in adipocytes, and its overexpression enhances TG deposition in 
cells, my aim in the present study is to examine its potential role in the 
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physiological regulation of lipolysis by TNF-α and catecholamines.  In order to 
study the regulation of FSP27 by TNF-α, and catecholamines, first, I studied 
the regulation of FSP27 in adipocytes in the basal state.  The data presented 
here show that FSP27 is under the transcriptional regulation of PPARγ, the 
most important transcription factor in adipocytes (231).  It is later confirmed 
that PPARγ2 binds to the PPARγ response elements on FSP27 promoter in 
adipocytes to drive FSP27 expression (246).  FSP27 is also observed to be 
PPARγ target gene in hepatocytes (264).  Furthermore, the studies in this 
thesis show that FSP27 has extremely rapid turnover with a half-life of less 
than 15 min.  It is ubiquitinated, and degraded via proteasome similar to 
CIDEA and other lipid droplet proteins such as perilipin and ATGL (209, 223, 
238).  These results are consistent with the paper published during 
preparation of this thesis (258).  I also report that TNF-α treatment of cultured 
adipocytes causes FSP27 depletion followed by decreased lipid droplet size, 
and lipolysis.  Conversely, sustained FSP27 expression in adipocytes from a 
viral expression vector protects against TNF-α action on lipid droplet size, and 
lipolysis.  This study highlights the importance of the lipid droplet protein 
FSP27 as a key target of TNF-α in the mechanism whereby this cytokine 
enhances lipolysis, and decreases lipid droplet size in adipocytes.   
 
On the other hand, isoproterenol, a potent lipolytic agent, surprisingly 
increases FSP27 levels by decreasing FSP27 ubiquitination, and 
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degradation.  The increase in FSP27 levels by isoporterenol is mediated via 
canonical PKA pathway, and increases in intracellular cAMP.  The adenoviral 
driven expression of FSP27 is able to protect against isoproterenol effect on 
lipid droplet size but not on lipolysis as we see larger and fewer lipid droplets 
associated with robust lipolysis when the adipocytes expressing adenoviral 
FSP27 are treated with isoproterenol.  This suggests that catecholamine 
mediated lipolysis, and change in lipid droplet morphology are distinct 
processes, and catecholamine leads to lipolysis in adipocytes through a 
pathway different from TNF-α and FSP27. 
 
This study highlights the importance of the lipid droplet protein FSP27 as a 
key target of TNF-α and β-adrenergic agonists in the mechanisms whereby 
these agents modulate lipolysis in adipocytes.  
 
EXPERIMENTAL PROCEDURES 
 
Materials- Affinity purified rabbit polyclonal FSP27 antibody was generated in 
the lab and also was kindly provided by Drs. Kasuga and Nishino, Kobe 
University Graduate School of Medicine, Kobe.  Polyclonal perilipin antibody 
was purchased from Fitzgerald (20R-PP004).  Polyclonal GFP antibody 
(2555), monoclonal HA antibody (2367) and monoclonal ATGL antibody 
(2439) were purchased from Cell Signaling. Monoclonal Ubiquitin antibody 
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P4D1 (sc-8017) was purchased from santa cruz and Vti1α from BD 
Transduction Laboratory (611220) Recombinant murine TNF-α (654245), 
cycloheximide (2397650), and MG-132 (474790) were obtained from 
Calbiochem.  Isoproterenol was purchased from Sigma (15627-56).  8-
Bromo-cAMP (CN-115), Forskolin (CN-100), and KT-5720 (EI-199) were 
obtained from Enzo Life Sciences, Leupeptin, Aprotinin from Roche, and 
NH4Cl from EMD. 
 
siRNA- All siRNAs were purchased from Dharmacon (Chicago).  The siRNA 
sequences were: Scr: 5’-CAGUCGCGUUUGCGACUGG-3’; FSP27: 5’-
CAACUAAGAAGAUCGAUGUUU-3’; ATGL: 5’- 
GCACAUUUAUCCCGGUGUAUU-3’; PKAca: 5’-
GUGGUUUGCCACGACUGACUU-3’; PKAcb: 
5’AGAGUUUCUAGCCAAAGCCUU-3’ 
 
Cell Culture and siRNA Transfection in 3T3-L1 Adipocytes- 3T3-L1 fibroblasts 
were cultured in Dulbecco’s modified Eagle’s medium supplemented with 
10% fetal bovine serum, 50µg/ml penicillin, and 50µg/ml streptomycin 
(complete DMEM).  After they reached quiescence, they were differentiated 
into adipocytes as previously described (265).  Adipocytes that were 
differentiated for four days were transfected with siRNA duplexes using a 
Biorad electroporator also described previously (265, 266). 
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Generation of Adenovirus and Infection of Adipocytes with Adenovirus- The 
coding sequence of mouse FSP27 with an HA tag on the N-terminal end was 
cloned into the pAdTrack adenoviral vector in Sal1/BglII restriction enzyme 
sites in the multiple cloning region.  The construct was confirmed by 
sequencing.  The construct was then linearized by Pme1 digestion and 
transformed into BJ5813 electrocompetent cells (Stratagene) to integrate the 
construct by homologous recombination into adenoviral backbone as 
described for the Adeasy system for viral vector generation (267).  Empty 
vector with GFP was used as control.  Expression of HA tagged FSP27 and 
GFP were standardized with titration and confirmed with western blot analysis 
using FSP27, HA, and GFP antibodies.  For infection of adipocytes, control or 
FSP27 adenovirus was directly added for 24hr to adipocytes on the fourth day 
after initiation of differentiation.  At the end of 24 hrs, the media was changed 
to fresh complete DMEM and cells were cultured for another 48 hr before 
harvesting.  All experiments were designed such that the cells had been 
exposed to virus 72 hours prior to harvesting.  
 
TNF-α and Isoproterenol Treatment, and Assay to Measure Glycerol 
Release- To treat adipocytes with TNF-α or isoproterenol, adipocytes were 
washed with PBS once.  Then 10 ng/ml TNF-α or 10 µM isoproterenol was 
added to phenol red free high glucose DMEM supplemented with 1% sodium 
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pyruvate, 1% L-glutamine, 0.1% biotin, 10% fetal bovine serum, 1% of 
penicillin, and 1% of streptomycin for 16hr or 3hrs respectively.  For serum 
starvation, cells were washed with PBS once, and phenol red free high 
glucose DMEM supplemented with 1% sodium pyruvate, 1% L-glutamine, 
0.1% biotin, and 2% bovine serum albumin was added overnight, and then 
the cells were treated with TNF-α.  After TNF-α or isoproterenol treatment the 
media was collected and assayed for glycerol content using a commercial 
colorimetric assay kit from Sigma as per manufacturer’s protocol. 
 
FSP27 stability Assay: Mature 3T3-L1 adipocytes were treated with 5µg/ml 
Leupeptin, 5µg/ml Aprotinin, 10 µM MG132, or 2.5 mM NH4Cl for 2 hrs, 
protein harvested with SDS lysis buffer, and analyzed with western blotting.  
For cycloheximide chase studies, mature adipocytes were washed with PBS 
and treated with 5µg/ml cycloheximide for 15, 30, and 60 min, then protein 
harvested with SDS lysis buffer and analyzed with western blotting.  
 
Detection of FSP27 ubiquitination: Mature 3T3-L1 adipocytes were treated 
with 10µM MG132 alone or in combination with 10ng/ml TNF-α, or 10µM 
isoproterenol for 3 hr.  The cells were washed twice with ice cold PBS and 
harvested with RIPA buffer containing 0.5% SDS.  The lysate was passed 
through syringe and precleared with Protein A beads for 1 hr.  FSP27 was 
immunoprecipitated with either non-immune rabbit IgG or Rabbit FSP27 
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antibody from the precleared lysate diluted with lysis buffer to final SDS 
concentration of 0.1%.  The immunoprecipitated protein was analyzed with 
western blot and probed with ubiquitin, and FSP27 antibody.  
 
Oil Red-O Staining for Lipid Droplets- Adipocytes grown on coverslips were 
washed three times with cold PBS, fixed in 4% paraformaldehyde for 10 mins, 
permeabilized and blocked with 0.05% Triton X-100 and 5% fetal bovine 
serum in PBS for 30 mins.  Oil Red-O (0.4%) in isopropyl alcohol solution was 
mixed with distilled water in the ratio of 60:40 and filtered through 0.45µm 
filters.  This freshly prepared Oil red-O solution was added to permeabilized 
cells for 30 mins.  These cells were then washed three times with ice cold 
PBS and mounted using Prolong Gold + DAPI mounting medium (Invitrogen), 
and lipid droplets imaged by confocal microscopy with a X60 Nikon PlanApo 
objective.  All images were identically exposed in any given experiment.  
 
Confocal Microscopy- Images were taken using a Zeiss Axiophot microscope 
with Hamamatsu digital camera and processed with Metamorph Imaging 
software (version 6.1).  Quantitation of the lipid droplet size was done using 
Axiovision digital imaging software (version 4.1) by selecting individual lipid 
droplets or groups of lipid droplets where appropriate. 
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RNA Isolation and Quantitative Reverse Transcription-PCR- Total RNA from 
3T3-L1 adipocytes were isolated using TRIzol Reagent (Invitrogen) following 
the manufacturer’s protocol.  cDNA was synthesized from 1 µg of total RNA 
using iScript cDNA synthesis kit (Bio-Rad).  Quantitative real time PCR was 
done using a MyIQ  real-time PCR system with iQ SYBR Green mix (Bio-Rad) 
and specific primers to amplify the genes.  
 
Statistical Analysis- Results are expressed as mean ± S.E. and the 
significance of the change were assessed using Student’s t-test or one-way 
ANOVA test. 
RESULTS 
 
A. Regulation of FSP27 
 
FSP27 is a PPARγ  responsive gene - FSP27 is highly expressed in 
adipocytes that are under the transcriptional control of factor PPARγ.  In 
addition, FSP27 is a lipid droplet protein, and PPARγ promotes lipid 
accumulation in adipocytes.  Therefore, I tested if FSP27 is one of the target 
genes of PPARγ.  3T3-L1 adipocytes were transfected with PPARγ siRNA on 
the fourth day of differentiation, and RNA was harvested to measure PPARγ 
and FSP27 transcripts using real time PCR.  Depletion of PPARγ by 90% 
decreased FSP27 to a similar extent suggesting that FSP27 is a PPARγ 
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target gene (Fig. 2.1 A).  Other studies had also shown that FSP27 mRNA 
progressively increased during adipocyte differentiation (235).  It had later 
been confirmed by the study that showed PPARγ2 binds to -219/-207 
promoter region in FSP27 that contains a PPARγ responsive element, and 
drives the transcription of FSP27 (246).  Furthermore, in hepatocytes also, 
the expression of FSP27 was markedly decreased in ob/ob mice deficient in 
PPARγ (264).  These data show that FSP27 is one of the PPARγ responsive 
genes. 
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Fig. 2.1. FSP27 is a PPARγ responsive gene.  A. Mature 3T3-L1 adipocytes 
were transfected with Scr or PPARγ siRNA for 72 hr and the harvested RNA 
was analyzed for PPARγ and FSP27 mRNA using real time PCR.  There was 
about 90% depletion of FSP27 mRNA in parallel to similar depletion in PPARγ 
mRNA.  Data expressed as mean ± SE of three different experiments. 
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FSP27 has a short half-life and is degraded by proteasome – Previous 
studies have shown that FSP27 depletion increases lipolysis in adipocytes 
while FSP27 expression promotes enlarged lipid droplet formation in COS 
cells and preadipocytes (233, 234).  These data suggest that the changes in 
cytosolic FSP27 levels could modulate lipid metabolism or storage, and could 
be a mechanism by which various stimuli modulate lipolysis. Therefore, in 
order to study the role of FSP27 in regulation of lipolysis in response to 
various lipolytic stimuli, I studied the regulation of FSP27 protein levels.  First 
I determined the stability of FSP27 by treating mature adipocytes with 5µg/ml 
of cycloheximide to block new protein synthesis and measured intact FSP27 
protein.  I found that FSP27 is an unusually short-lived protein and has a half-
life of less than 15 min (Fig. 2.2 A, B).  Addition of the proteasome inhibitor 
MG132 inhibited the degradation of FSP27 (Fig. 2.2C,D).  However, neither 
the general peptidase inhibitors aprotinin and leupeptin nor the lysosome 
inhibitor NH4Cl was able to prevent degradation of FSP27 (Fig. 2.2C,D).  
Another group also published recently showing similar results that FSP27 is a 
fast turned-over protein and is degraded via proteasome (258). 
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C.                                               D. 
   
                                 
 
Fig. 2.2. FSP27 has a short half-life and is degraded by proteasome after 
ubiquitination.  A. Representative western blot of adipocyte lysates following 
15, 30 and 60 minutes treatment with 5µg/ml of cycloheximide compared to 
untreated (0) cells shows rapid degradation of FSP27. B. Densitometric 
measurement of FSP27 protein levels after cycloheximide treatment as in (A).  
C. Representative western blot of FSP27 shows protection of FSP27 from 
degradation in lysates from cells treated with the proteasome inhibitor 
MG132, but not by peptidase inhibitors leupeptin (Leu) or aprotinin (Aprot), or 
lysosomal inhibitor NH4Cl.  D. Densitometric measurement showing protection 
of FSP27 by MG132.  Data shown representative of six separate experiments. 
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FSP27 is ubiquitinated to target for proteasomal degradation- It has been 
well established that the proteins degraded via proteasome are ubiquitinated 
as a signal for degradation (268).  This is also observed in other lipid droplet 
proteins such as perilipin, ADRP, and one of the CIDE proteins, CIDEA (209, 
223, 238).  Therefore, I tested whether FSP27 is ubiquitinated for 
proteasomal degradation.  In order to detect ubiquitination of FSP27, mature 
3T3-L1 adipocytes were treated with MG132 for 3 hr to block proteasomal 
degradation of FSP27, and harvested using RIPA buffer containing 0.5% 
SDS.  Equal amounts of protein were taken, diluted with lysis buffer to get 
final concentration of 0.1% SDS, and FSP27 was immunoprecipiated 
overnight using anti-FSP27 antibody, then analysed by Western blot anti-
ubiquitin antibody and anti-FSP27 antibody.  Upon blockade of proteasomal 
degradation with MG132, multiple bands detectable with anti-ubiquitin 
antibody as well as FSP27 antibody could be detected specifically in FSP27 
immunoprecipitates (Fig. 2.3 B,C).  These results suggest that FSP27 protein 
is rapidly destroyed by ubiquitination and proteasomal degradation, raising 
the possibility that FSP27 protein levels could be quickly modulated as a 
mechanism for regulation of lipolysis.  These data are consistent with a paper 
published as we were finalizing our manuscript that also showed FSP27 has 
a short half life and is ubiquitinated and degraded via the proteasome (258). 
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Fig. 2.3. FSP27 is ubiquitinated to target for proteasomal degradation.  
Mature 3T3-L1 adipocytes were treated with MG132 for 3 hr, and harvested in 
RIPA buffer containing 0.5% SDS.  A. Total lysate of 3T3-L1 adipocytes with 
or without MG132.  B. FSP27 immunoprecipitated with endogenous FSP27 
antibody or non-immune rabbit IgG (IgG), and probed with anti-ubiquitin 
antibody shows increased ubiquitination in presence of MG132.  C. FSP27 
immunoprecipitated using endogenous FSP27 antibody or non-immune rabbit 
IgG (IgG), and probed with anti-FSP27 antibody shows polyubiquitinated 
FSP27.  Data shown representative of four separate experiments. 
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B. Suppression of FSP27 by TNF-α to mediate lipolysis in 3T3-L1 
adipocytes 
 
TNF-α decreases FSP27 levels in 3T3-L1 adipocytes - TNF-α is an 
inflammatory cytokine that has profound effects on adipocytes including 
stimulation of lipolysis and downregulation of numerous adipocyte-expressed 
genes.  Since FSP27 depletion causes increased lipolysis in adipocytes I 
sought to determine whether TNF-α alters FSP27 levels when adipocytes are 
treated with TNF-α at concentrations that stimulates lipolysis.  The lowest 
concentration and shortest duration of TNF-α treatment that stimulates 
lipolysis optimally was established by treating fully differentiated mature 3T3-
L1 adipocytes with various concentrations of TNF-α for different time periods 
and measuring rates of glycerol release. The strongest effects on lipolysis 
were obtained when cultured adipocytes were treated with 10 ng/ml TNF-α for 
16 hrs. Under these conditions about a 1.5 fold increase in glycerol release 
from adipocytes was observed in response to the cytokine. Although, this 
concentration of TNF-α is comparable to the plasma TNF-α level in NOD 
mice that developed diabetes after treatment with interferon-γ and 
lipopolysaccharide (269), the local concentration of TNF-α in adipocytes could 
be higher than circulating plasma levels because of increased TNF-α 
expression in adipocytes in obesity and inflammation (270). Nevertheless, this 
TNF-α concentration is likely similar to low grade inflammation associated 
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with obesity and insulin resistance. Thus, for the subsequent experiments, 
this treatment condition was used.  
 
After treatment of mature adipocytes with TNF-α, FSP27 and perilipin mRNA 
were analyzed using quantitative real time PCR. Treating adipocytes with 
TNF-α significantly decreased the mRNA transcripts of both FSP27 and 
perilipin (Fig. 2.4 A). Downregulation of FSP27 mRNA after TNF-α treatment 
was also observed previously with Northern blotting (235), and 
downregulation of perilipin by the cytokine is consistent with a previous study 
(174). The effect of TNF-α on the protein levels of FSP27 and perilipin were 
also analyzed using Western blotting, which showed a significant decrease in 
FSP27 and perilipin protein levels after TNF-α treatment (Fig 2.4 B, C). 
Therefore, TNF-α treatment of adipocytes, at the dose stimulating lipolysis, 
downregulates FSP27 both at mRNA and protein levels. 
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Fig. 2.4. TNF-α decreases FSP27 levels in 3T3-L1 adipocytes.  A. RT-PCR 
showing decreased FSP27 and perilipin (PLIN) mRNA in mature 3T3-L1 
adipocytes treated with 10ng/ml TNF-α for 16 hrs.  B. Western Blot analysis 
using FSP27, PLIN, and Actin (loading control) antibodies showing decrease 
in FSP27 and PLIN protein levels in 3T3-L1 adipocytes treated with 10 ng/ml 
TNF-α for 16 hrs.  C. Densitometry showing decrease in FSP27 and PLIN 
protein levels after TNF-α treatment. Data expressed as means ± S.E for six 
different experiments, p-value calculated using Student’s t test, p  *<0.05, ** < 
0.0005. 
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FSP27 depletion enhances TNF-α-stimulated lipolysis - To determine 
whether FSP27 protein downregulation by TNF-α plays a role in increased 
lipolysis, I first measured lipolysis in adipocytes after siRNA-mediated 
depletion of FSP27 with or without TNF-α treatment (Fig. 2.5).  Cultured 
adipocytes were transfected with either scrambled (Scr) or FSP27 siRNA, and 
glycerol release was measured in basal and TNF-α-treated cells.  Treatment 
of cells with TNF-a and silencing of FSP27 expression both caused a ~50% 
increase in glycerol release, while the combination of these treatments 
resulted in a 2-2.5 fold increase in lipolysis (Fig. 2.5 A).  Both FSP27 silencing 
and TNF-a treatment caused similarly dramatic decreases in FSP27 protein 
levels (Fig. 2.5 B,C).  Under these conditions TNF-α caused a smaller but still 
significant decrease in perilipin levels as previously reported (174).  However, 
FSP27 depletion by gene silencing did not significantly change perilipin levels 
although we detected increased glycerol release, suggesting that perilipin is 
unable to compensate for decreased FSP27 levels in preventing lipolysis 
under these conditions.  Thus, depletion of FSP27 correlates with increased 
glycerol release, implicating control of FSP27 as a potential mechanism of 
regulation of lipolytic rate. 
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Fig. 2.5. TNF-α treatment of 3T3-L1 adipocytes increases lipolysis that is 
enhanced by further depletion of FSP27 using siRNA.  A. Glycerol released in 
media measured in 3T3-L1 adipocytes electroporated with scr or FSP27 
siRNA, and treated with 10 ng/ml TNF-α for 16 hrs.  siRNA mediated 
depletion of FSP27 in TNF-α treated cells causes maximum increase in 
glycerol release.  B. Western blot analysis using FSP27, perilipin (PLIN), and 
Actin antibodies showing FSP27 and PLIN protein levels in control and TNF-α 
treated conditions.  C. Densitometric measurement of fig. B showing 
decrease in FSP27 levels with siRNA and TNF-α treatment.  Data expressed 
as means ± S.E for six different experiments, p-value calculated using 
ANOVA, p  *<0.05, ** < 0.0005 
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TNF-α mediated decrease in FSP27 precedes the diminution of lipid 
droplet size and increase in glycerol release – To further address potential 
regulation of lipolysis by FSP27 I examined the temporal relationships 
between TNF-α-mediated changes in decreased FSP27 protein levels, lipid 
droplet morphology and adipocyte lipolytic rates.  Mature 3T3-L1 adipocytes 
were treated with 10ng/ml TNF-α for various times between 30 min and 16 hr 
as shown in Figure 2.6, and the media collected and assayed for glycerol 
release.  There was a significant increase in lipolysis starting at 2 hr after 
addition of TNF-α to the adipocytes, but the highest increase in lipolytic rate 
occurred at 16hr (Fig. 2.6 D).  Whereas the FSP27 protein levels started to 
decrease as early as 30 min after addition of TNF-α treatment, the protein 
was almost completely undetectable after 2 hr of treatment (Fig. 2.6 E, F).  
The size of lipid droplets within adipocytes was already reduced after only 30 
min of TNF-α treatment and increased numbers of lipid droplets could also be 
observed at this time (Fig. 2.6 A, B, C).  These changes became statistically 
significant after 1 hr of TNF-α treatment.  Thus, the rapid TNF-α-mediated 
decrease in FSP27 protein preceded formation of numerous smaller lipid 
droplets.  Increased glycerol release follows these events suggesting that the 
change in lipid droplet morphology that results from loss of FSP27 facilitates 
subsequent events that increase lipolytic rate. 
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FIGURE 2.6 
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FIGURE 2.6. TNF-α mediated decrease in FSP27 precedes the diminution of 
lipid droplet size and increase in glycerol release.  Mature 3T3-L1 adipocytes 
were treated with TNF-α for 30 min, 1hr, 2hr, 4hr, 8hr and 16hr.  A. Confocal 
microscope image showing lipid droplets stained with Oil Red-O (red), and 
nucleus stained with DAPI (blue).  Images shown are representative of 90 
random fields imaged in three different experiments.  B. Quantification of lipid 
droplet size using MetaMorph imaging software.  Data shown is mean ± S.E 
of representative 10 cells for each condition from different experiments.  C. 
Quantification of numbers of lipid droplets per cell for each time point.  D. 
Glycerol released into media after 10 ng/ml TNF-α treatment for 30mins, 1 hr, 
2 hr, 4 hr, 8 hr, and 16 hr.  E. Western Blot analysis showing the FSP27 
protein after 10 ng/ml TNF-α treatment for 30 min, 1 hr, 2 hr, 4 hr, 8 hr, and 
16 hr.  F. Densitometry showing decrease of FSP27 protein after TNF-α 
treatment.  Data expressed as mean ± S.E for three different experiments, p-
value calculated using ANOVA, p  *<0.05, ** < 0.005 
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Expression of adenoviral FSP27 protects against TNF-α mediated 
lipolysis and reduced lipid droplet size - To test the hypothesis that the 
action of TNF-α on adipocyte lipolysis relies on its ability to deplete FSP27 
protein levels, we developed a strategy to maintain FSP27 protein levels in 
adipocytes in the presence of TNF-α.  To achieve this, we generated an HA-
tagged FSP27 construct incorporated into an adenovirus expression system 
that also elicits GFP expression from a different promoter,  thus maintaining 
FSP27 levels when the endogenous FSP27 expression is reduced by TNF-α.  
A virus expressing GFP alone was used to infect control cells. Using these 
reagents, recombinant adenovirus-directed expression of HA-FSP27 
remained constant even when TNF-α treatment depleted endogenous FSP27 
(Fig. 2.7 A).  Under these conditions the expected decrease in perilipin 
protein level in response to the cytokine was also observed. In spite of this, 
adenovirus-mediated expression of HA-FSP27 in cultured adipocytes blocked 
the increase in lipolysis caused by TNF-α (Fig. 2.7 B).  There was also a 
small but significant decrease in lipolysis in control adipocytes that were not 
treated with TNF-α.  
 
Both TNF-α treatment, and FSP27 depletion in cultured adipocytes have 
been shown to cause a time dependent change in the morphology of lipid 
droplets such that they are smaller in size and increased in number (197, 
233).  Therefore, we wanted to test whether high FSP27 expression could 
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prevent such apparent lipid droplet morphology change upon TNF-α 
treatment.  Control or HA-FSP27 adenovirus were added to differentiated 
adipocytes seeded on coverslips, and treated with 10 ng/ml TNF-α.  The cells 
were then stained with Oil Red-O to visualize lipid droplets. Treatment of the 
cultured adipocytes with TNF-α for 16 hr caused formation of smaller and 
more abundant lipid droplets compared to control cells, as expected.  
However, TNF-α treatment of adipocytes expressing HA-FSP27 maintained 
larger, fewer lipid droplets compared to cells expressing GFP alone or 
uninfected adipocytes in the same field  (Fig. 2.7 C). These results 
demonstrate that sustained FSP27 expression can block the effects of TNF-α 
on both lipid droplet morphology and lipolysis even though perilipin levels are 
diminished. This suggests that depletion of FSP27 is part of the mechanism 
by which TNF-α increases lipolysis in adipocytes.  
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Fig. 2.7.  Expression of adenoviral FSP27 protects against TNF-α mediated 
lipolysis and reduced lipid droplet size.  3T3-L1 adipocytes were infected with 
control virus (Ad-GFP) or HA-FSP27 expressing virus (Ad-HA-FSP27) on the 
fourth day of differentiation.  On the fifth day, cells were serum starved 
overnight, then treated with 10 ng/ml TNF-α for 24 hrs and analyzed for 
protein, glycerol release and lipid droplet morphology.  A. Western blot 
analysis using FSP27, HA, GFP, perilipin (PLIN), Actin, and Vti1α antibodies 
showing maintenance of HA tagged FSP27 protein levels even after 
treatment of TNF-α.  Actin is the loading control for HA, GFP, and PLIN, and 
Vti1α is the loading control for FSP27.  B. Glycerol released into the media in 
24 hr with or without TNF-α treatment.  C. Confocal microscope image 
showing lipid droplets stained with Oil Red-O (red), nucleus stained with DAPI 
(blue), green representing GFP expression in 3T3-L1 adipocytes expressing 
Ad-GFP or Ad-HA-FSP27 in presence or absence of TNF-α.  Data expressed 
as mean ± S.E for five individual experiments, p-value calculated using 
ANOVA, p  *<0.05, ** < 0.0005 
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FSP27 depletion and TNF-α both require ATGL to regulate lipolysis - 
Mouse adipocytes contain multiple lipases including HSL and ATGL that 
participate in mediating basal and stimulated lipolysis (184, 190-193).  
Consistent with the concept that these lipases are required for lipolysis, the 
sizes of lipid droplets were reported to be larger in ATGL- or HSL-depleted 
adipocytes (184, 189, 271).  Thus, we examined whether the lipase ATGL is 
required to observe the enhanced lipolysis caused by FSP27 depletion and 
TNF-α treatment.  We used siRNA to deplete the lipase ATGL in 3T3-L1 
adipocytes and assayed glycerol release.  As shown in Fig. 2.8 A, ATGL 
depletion by siRNA prevented stimulation of lipolysis by TNF-α treatment or 
FSP27 silencing.  Isoproterenol was also not able to enhance lipolysis in the 
absence of ATGL (Fig. 2.8 B) as expected and reported previously (184, 190-
192).  These results strongly suggest that TNF-α and FSP27 regulate 
adipocyte lipolysis through the canonical lipases regulated by 
catecholamines, which includes TG hydrolysis catalyzed by the lipase ATGL. 
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Fig. 2.8. FSP27 depletion and TNF-α both require ATGL to mediate lipolysis.  
3T3-L1 adipocytes were electroporated with Scr, FSP27, ATGL, or FSP27 
and ATGL siRNA on the fourth day of differentiation.  On the sixth day cells 
were treated with 10 ng/ml TNF-α for 16 hr.  A.  Glycerol release in media 
after 16 hrs of 10 ng/ml TNF-α treatment.  B. Glycerol release in media after 3 
hr of 10 µM Isoporterenol treatment.  Data shown is mean± S.E of five 
individual experiments, p-value calculated using ANOVA, p  *<0.05.  The 
attenuation of glycerol release after TNF-α treatment under ATGL KD and/or 
FSP KD is also significant (p  *<0.05). 
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  C. Stabilization of FSP27 by isoproterenol and its effect on 3T3-
L1 adipocyte lipolysis 
 
Isoproterenol stabilizes FSP27 by delaying its degradation in 3T3-L1 
adipocytes – We also tested the role of FSP27 in β-adrenergic receptor-
stimulated lipolysis, which is a normal physiological pathway of starvation-
induced lipolysis in adipocytes. First we tested the effect of the β-adrenergic 
receptor agonist isoproterenol on FSP27 levels.  Mature 3T3-L1 adipocytes 
were treated with 10µM isoproterenol for 3 hr, and protein lysate were 
harvested and analyzed with western blotting.    Surprisingly, treatment of 
mature adipocytes with 10µM isoproterenol for 3 hr increased FSP27 protein 
levels in a time dependent manner without significant effects on mRNA levels 
(Fig. 2.9 A,B,E).  Since FSP27 is a short lived protein, the effects of 
isoproterenol treatment on degradation of FSP27 in adipocytes was 
determined by treating with 10 µM isoproterenol for 3 hrs, and then treating 
with cycloheximide to block new protein synthesis. We observed delayed 
degradation of FSP27 after isoproterenol treatment, increasing its half-life 
from about 15 minutes to more than 1 hour (Fig. 2.9 C, D), consistent with the 
data published during preparation of this thesis (258).  
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Fig. 2.9.  Isoproterenol stabilizes FSP27 by delaying its degradation in 3T3-L1 
adipocytes.  A.  Mature adipocytes treated with 10µM isoproterenol (Iso) for 
15, 30, 60, 120 or 180 minutes shows increased FSP27 protein level with 
isoproterenol treatment compared to the control (0).  B.  Densitometry 
showing increased FSP27 protein level after 180mins of 10µM isoproterenol 
treatment of mature adipocytes.  C.  Mature adipocytes treated with 10µM 
isoproterenol for 3 hr, pulsed with 5µg/ml cycloheximide and chased for 15, 
30 and 60 minutes show delayed degradation of FSP27 in presence of 
isoproterenol compared to control.  D.  Densitometry of FSP27 protein levels 
show delayed FSP27 degradation in presence of isoproterenol.  E.  Mature 
adipocytes treated with 10µM isoproterenol were harvested for RNA and 
analysed for FSP27 mRNA shows no change in FSP27 transcript with 
isoproterenol treatment.  Data expressed as mean ± S.E for six individual 
experiments.  
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Ubiquitination of FSP27 in response to TNF-α and isoproterenol- As 
isoproterenol upregulated FSP27 protein by delaying its degradation, I 
hypothesized that isoproterenol would decrease FSP27 ubiquitination.  
Ubiquitination of FSP27 might also be regulated in response to TNF-α, which 
decreases FSP27 levels.  Mature adipocytes were treated with the 
proteasome inhibitor MG132 alone or in combination with isoproterenol or 
TNF-α for 3 hrs, then harvested in RIPA lysis buffer containing 0.5% SDS and 
MG132.  Equal amounts of protein lysate were diluted in lysis buffer to the 
final SDS concentration of 0.1%, and immunoprecipitated using anti-FSP27 
antibody or rabbit non-immune IgG, then FSP27 and ubiquitinated proteins 
were detected in FSP27 immunoprecipitates.  Analysis of FSP27 using 
ubiquitin antibody showed decreased ubiquitination of FSP27 in response to 
isoproterenol (Fig. 2.10 B, C).  Conversely ubiquitination of FSP27 in 
response to TNF-α was similar to the MG132 only treatment. Thus, the 
observed stabilization of FSP27 protein in response to isoproterenol 
treatment correlates with reduced ubiquitin conjugation to FSP27. 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Fig. 2.10.  Ubiquitination of FSP27 in response to TNF-α and isoproterenol.  
Mature adipocytes were treated with MG132 alone or with TNF-α or 
isoproterenol, FSP27 immunoprecipitated using FSP27 antibody (F) or non 
immune rabbit IgG (G), and probed with anti-ubiquitin (Ub) and anti-FSP27 
antibody.  A.  Western blot showing total lysate of adipocytes treated with 
MG132 alone or with TNF-α or isoproterenol.  B.  FSP27 immunoprecipitated 
with FSP27 antibody and probed with anti-ubiquitin antibody.  C.  FSP27 
immunoprecipitated with FSP27 and probed with anti-FSP27 antibody.  Data 
shown representative of four separate experiments. 
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Isoproterenol stabilizes FSP27 through PKA pathway – Because β-
adrenergic receptor stimulation increases cAMP levels and activates PKA, we 
next tested whether isoproterenol-mediated stabilization of FSP27 is via this 
same canonical PKA pathway.   Depletion of PKA using siRNA decreased 
basal FSP27 level and inhibited upregulation of FSP27 after isoproterenol 
treatment (Fig. 2.11 A).  Effectiveness of the PKA knockdown was evidenced 
by lack of perilipin phosphorylation (detected as a shifted band in 
isoproterenol treated cells) upon PKA silencing (Fig. 2.11 A).  FSP27 
upregulation after isoproterenol treatment was inhibited also by PKA inhibitor 
KT5720, while the effect of isoproterenol on FSP27 was mimicked by either 
the adenylate cyclase activator forskolin, or 8-bromo-cAMP, a soluble cAMP 
analogue, in combination with IBMX, a phosphodiesterase inhibitor (Fig. 2.11 
B). Therefore, β-adrenergic stimulation signals via increased intracellular 
cAMP levels and PKA activation to upregulate FSP27 protein by delaying its 
degradation. 
 
In next set of experiments I tested whether FSP27 is phosphorylated by PKA 
in response to isoproterenol.  HA tagged FSP27 was expressed in 3T3-L1 
adipocytes using adenovirus, and treated with 10 µM isoproterenol for 3 hr.  
Protein lysates were harvested using RIPA lysis buffer containing 0.5% SDS.  
Equal amounts of protein were taken, diluted with lysis buffer to final SDS 
concentration of 0.1%, and was used to immunoprecipitate HA-FSP27 using 
  89 
anti-HA antibody.  No phosphorylated protein was detected in the 
immunoprecipitates when probed with anti PKA substrate antibody.  The 
efficiency of immunoprecipitation was established by detection of HA-FSP27 
when probed with anti-HA antibody (Fig. 2.11 E).  Although these results 
suggest that FSP27 is not phosphorylated in response to isopropterenol 
treatment, its confirmation requires further investigations.   
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C.                 D.                                                     E.         
 
 
Fig. 2.11.  Isoproterenol stabilizes FSP27 through PKA pathway.  A.  
Adipocytes with transfected with either Scr or PKA siRNA and treated with or 
without 10µM isoproterenol (Iso).  The effect of isoproterenol on FSP27 is 
abrogated when PKA is knocked down.  The absence of perilipin (PLIN) 
phosporylation despite isoproterenol treatment in adipocytes treated with PKA 
siRNA is used as the positive control.  B.  Mature adipocytes were treated 
with 10µM isoproterenol, 5µM Forskolin (For), 1mM 8-bromo-cAMP 
(BcAMP)+ IBMX or 80 µM KT5720 + 10µM isoproterenol.  The effect of 
isoproterenol on FSP27 is mimicked by Forskolin, BcAMP, and inhibited by 
KT5720.  C.  Western Blot of total lysate from 3T3-L1 adipoctes infected with 
control virus (Ad-GFP) or HA-FSP27 adenovirus (Ad-HA-FSP27) in presence 
or absence of isoproterenol.  D.  FSP27 mmunoprecipitated with anti HA 
antibody or non-immune IgG from Ad-GFP or Ad-HA-FSP27 expressing 3T3-
L1 adipocytes in presence or absence of isoproterenol, and probed with anti-
PKA substrate antibody does not show any phophorylated band that may 
correspond to FSP27.  E.  FSP27 mmunoprecipitated with anti HA antibody or 
non-immune IgG from Ad-GFP or Ad-HA-FSP27 expressing 3T3-L1 
adipocytes in presence or absence of isoproterenol and probed with anti-HA 
antibody show the immunoprecipitated HA-FSP27. 
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Isoproterenol-mediated up regulation of FSP27 is independent of 
isoproterenol-mediated lipolysis – A recently published study has shown 
that the up regulation of FSP27 after isoproterenol treatment is dependent on 
fatty acid reesterification, and depletion of diacyl glycerol transferase (DGAT), 
an enzyme involved in reesterification, prevented FSP27 up regulation in 
response to isoproterenol (258).  Thus, I wanted to test whether isoproterenol 
mediated lipolysis is an essential event that releases FFAs, which during 
reesterification stabilizes FSP27.  In order to examine this, I blocked lipolysis 
in 3T3-L1 adipocytes by silencing ATGL, the lipase necessary for stimulated 
lipolysis.  3T3-L1 adipocytes were transfected with Scr or ATGL siRNA using 
a BioRad electroporator.  After 72 hr of transfection, adipocytes were treated 
with 10 µM isoproterenol, and media was collected to assay glycerol release.  
The decrease in glycerol release observed in ATGL depleted adipocytes was 
consistent with previous results reporting ATGL was required for 
catecholamine mediated lipolysis (184, 190-192).  In addition, significant up 
regulation of FSP27 after isoproterenol treatment was observed in adipocytes 
even when lipolysis was blunted in ATGL depleted condition (Fig. 2.12 B, C).  
Therefore, these results suggest that catecholmine-mediated lipolysis is not 
required for FSP27 stabilization after catecholamine treatment of adipocytes. 
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A.                                   B.                             C. 
   
 
Fig. 2.12. Isoproterenol-mediated up regulation of FSP27 is independent of 
isoproterenol-mediated lipolysis.  3T3-L1 adipocytes transfected with Scr or 
ATGL siRNA, and then treated with 10 µM isoproterenol (Iso) for 3 hr.  A.  
Glycerol released in media showing decreased lipolysis in ATGL depleted 
adipocytes.  B.  Western blot analysis showing decreased ATGL in ATGL 
depleted cells whereas FSP27 was upregulated in both Scr and ATGL siRNA 
treated adipocytes in response to isoproterenol.  C.  Densitometry of western 
analysis in fig. B showing significant increases in FSP27 in response to 
isoproterenol despite decreased ATGL and lipolysis.  Data expressed as 
mean ± S.E for three different experiments, p-value calculated using ANOVA, 
p  *<0.05. 
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Expression of adenoviral FSP27 protects against Isoproterenol 
mediated lipid droplet size diminution but not against lipolysis – The up 
regulation of FSP27, a protein with lipid droplet protective function, upon 
treatment with potent lipolytic agent, catecholamine was unexpected and 
surprising.  This observation led to the hypothesis that the up regulation of 
FSP27 upon isoproterenol treatment could be a feedback mechanism to 
dampen excessive lipolysis after isoproterenol treatment.  Therefore, I tested 
if expression of HA-FSP27 to a higher level using adenovirus could attenuate 
effects of isoproterenol on lipolysis and lipid droplet size diminution.  3T3-L1 
adipocytes were infected with control adenovirus or HA-FSP27 adenovirus for 
72 hr as described previously, and treated with 10µM isoproterenol for 3hr.  
Using adenovirus, we were able to express FSP27 in excess of isoproterenol 
mediated up regulation of FSP27 (Fig. 2.13 A).  When adipocytes expressing 
HA-FSP27 were treated with 10µM isoproterenol for 3hrs, the normal sharp 
increase in lipolysis was observed (Fig. 2.13 B).  Since isoproterenol 
upregulated FSP27, it was possible that the protective effective of FSP27 on 
lipolysis was already saturated, and thus the adenovirus expressed FSP27 
did not have an additional protective effect.  Thus, I further tested whether 
there was any difference in the rate of lipolysis mediated by catecholamines 
in absence of FSP27.  FSP27 was depleted in 3T3-L1 adipocytes using 
siRNA, treated with 10µM isoproterenol for 3 hr, and the rate of glycerol 
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release in the media was measured using colorimetric assay at the end of 1hr 
and 3hr.  A previous study reported decreased responsiveness to 
isoproterenol after FSP27 knock-down using siRNA in adipocytes (272) but I 
observed robust increase in glycerol release after isoproterenol treatment 
even when FSP27 was depleted using siRNA.  Furthermore, the difference in 
the rate of glycerol release in response to isoproterenol in adipocytes treated 
with FSP27 compared to Scr siRNA was significantly higher at 3hr compared 
to 1 hr (Fig. 2.13 C,D).  These data suggested that the upregulation of FSP27 
after isoproterenol treatment could be an intrinsic mechanism to restrain the 
potent lipolytic effect of isoproterenol, as the rate of lipolysis was significantly 
increased if the upregulation of FSP27 by isoproterenol was prevented using 
siRNA.  The data also showed that isoproterenol mediated lipolysis involved a 
mechanism other than depletion of FSP27 and was different from the 
mechanism through which TNF-α mediated lipolysis. 
 
My previous results with TNF-α treatment of adipocytes have shown that 
lipolysis and lipid droplet size diminution are two separate processes.  Thus, it 
was possible that the increased expression of FSP27 from adenovirus might 
have a protective effect on isoproterenol mediated lipid droplet dispersion 
despite having no effect on lipolysis.  3T3-L1 adipocytes, infected with 
adenovirus expressing HA tagged FSP27, were treated with 10 µM 
isoporterenol for 3 hr. The lipid droplets were stained with oil red-O and 
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imaged with confocal microscope as described in experimental procedures.  
Interestingly, HA-FSP27 expression from adevnovirus was able to protect 
against isoproterenol mediated lipid droplet size diminution.  Isoprotenerol 
caused diminution of lipid droplet size in cells expressing GFP alone, or 
uninfected cells while those cells expressing FSP27 showed persistent larger 
lipid droplets even in presence of isoproterenol (Fig. 2.13 D).  Taken together, 
these data indicate that lipolysis and lipid droplet morphology change in 
response to isoproterenol are two distinct processes, supporting previous 
observations (183, 218), and FSP27 has a role in formation of larger lipid 
droplets independent of the lipolysis. 
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Fig. 2.13.  Expression of adenoviral FSP27 protects against Isoproterenol 
mediated lipid droplet size diminution but not against lipolysis.  3T3-L1 
adipocytes were infected control virus (Ad-GFP) or HA-FSP27 expressing 
virus (Ad-HA-FSP27) on the fourth day of differentiation.  On the seventh day, 
cells were treated with 10µM isoproterenol (Iso) for 3 hrs, and analyzed for 
protein, glycerol release and lipid droplet morphology.  A.  Western blot 
analysis using FSP27, HA, GFP, perilipin (PLIN), Actin, and Vti1α antibodies. 
Actin is the loading control for HA, GFP, and PLIN, and Vti1α is the loading 
control for FSP27.  B.  Glycerol released into the media in 3 hr from 
adipocytes infected with Ad-GFP or Ad-HA-FSP27, with or without 
isoproterenol treatment.  C. Glycerol released from 3T3-L1 adipocytes treated 
with Scr or FSP27 siRNA. D. Difference in the rate of glycerol release in 
response to isoproterenol from 3T3-L1 adipocytes treated with Scr or FSP27 
siRNA shows increased rate of lipolysis at 3hr compared to 1hr.  E.  Confocal 
microscope image showing lipid droplets stained with Oil Red-O (red), 
nucleus stained with DAPI (blue), green representing GFP expression in 3T3-
L1 adipocytes expressing Ad-GFP or Ad-HA-FSP27 in presence or absence 
of isoproterenol. Expressed as mean ± S.E for three individual experiments, 
p-value calculated using ANOVA for fig. B, and using t-test for fig. C, p  
*<0.05 NS; not significant. 
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DISCUSSION 
 
The present work as well as another recent study (258) show that FSP27 has 
a very short half-life, and that its rapid turnover is due to ubiquitination and 
degradation via the proteasome (Fig. 1).  These characteristics are similar to 
those of other lipid droplet proteins such as perilipin, ADRP and another CIDE 
protein: CIDEA (209, 223, 238).  Recent parallel studies also show that three 
lysine residues in the C-terminal region of FSP27 – K224, K226 and K236 are 
critical for ubiquitination and therefore the stability of FSP27 protein (258).  
Overexpression of mutant FSP27 lacking these three lysines stabilized 
exogenous and endogenous FSP27, and increased lipid droplet storage in 
adipocytes.  Our results advance this finding by demonstrating that acute 
regulation of FSP27 levels is one of the mechanisms by which external stimuli 
such as TNF-α modulate lipolysis  (Figures 2, 3, 5). 
 
The cytokine TNF-α has been reported to affect rates of lipolysis in 
adipocytes at multiple levels, including enhancing cAMP-dependent signaling 
pathways as well as altering amounts and activities of triglyceride lipases and 
other lipid droplet associated proteins (166, 176, 256, 273).  Here we show 
that TNF-α causes rapid and dramatic depletion of the lipid droplet protein 
FSP27 (Fig. 2.4).  This depletion precedes the decreased volume of lipid 
droplets and increased lipolysis (Fig. 2.6).  Remarkably, restoration of FSP27 
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protein levels by adenovirus-mediated expression in TNF-α-treated cells is 
sufficient to block both the droplet diminution and increased lipolysis induced 
by TNF-α treatment (Fig. 2.7).  This result suggests that downregulation of 
FSP27 is an essential and early step in the sequence of TNF-α-triggered 
events that leads to increased triglyceride turnover in adipocytes.  
 
The data presented here show a remarkable, near complete inhibition of 
FSP27 protein expression by TNF-α in cultured adipocytes.  We also observe 
a significant decrease in FSP27 mRNA after TNF-α treatment (Fig. 2.4 A) 
consistent with the results previously shown (235).  Thus the decrease in 
FSP27 protein level could be primarily due to the decrease in the FSP27 
transcript levels, although we have not ruled out other mechanisms affecting 
the protein itself.  A previous study has shown that TNF-α decreases the 
expression of a transcription factor, C/EBPα, corresponding to decreased 
activity of a FSP27 promoter-CAT reporter construct in cultured adipocytes.  
Thus, downregulation of FSP27 transcripts by TNF-α could be partly due to a 
decrease in C/EBPα levels (235, 262, 274).  Our results and other show that 
transcription of FSP27 is PPARγ dependent in adipocytes (Fig. 2.1 A, (246)), 
and in hepatocytes (264) and the effect of TNF-α on FSP27 transcription 
could be due to the previously observed decrease in PPARγ protein levels in 
TNF-α-treated adipocytes (275, 276).  TNF-α has also been reported to 
regulate lipolysis in 3T3-L1 adipocytes through MAP kinases (277), however 
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inhibition of these kinases was not able to block the depletion of FSP27 
transcripts (235).  The detailed molecular mechanisms whereby TNF-α 
downregulates FSP27 mRNA and protein is an important topic for future 
investigations. 
 
Based on previous work cited above, the depletion of FSP27 by TNF-α action 
could be one mechanism acting in parallel with other mechanisms by which 
TNF-α stimulates lipolysis in adipocytes.  For example, we observed that 
when FSP27 is depleted using siRNA and the cells are then treated with TNF-
α, the increase in glycerol release is greater than FSP27 depletion or TNF-α 
treatment alone (Fig. 2.5 A).  However, this also correlates with lower levels 
of FSP27 protein after FSP27 silencing with siRNA plus TNF-α treatment 
compared to either treatment alone (Fig. 2.5 B, C).  Importantly, there was no 
significant change in perilipin expression under these conditions. These data 
not only support the role of FSP27 in TNF-α stimulated lipolysis, but also 
indicate that the total lipolysis correlates with the level of FSP27 present in 
adipocytes.  The key role of FSP27 in TNF-α stimulated lipolysis is further 
supported by the ability of the FSP27 to block TNF-α-stimulated lipolysis in 
3T3-L1 adipocytes when there is sustained FSP27 expression using 
adenovirus infection (Fig. 2.7 B).  Consistent with the protection against 
lipolysis, the phenotype of the lipid droplets with FSP27 expression was large 
and few in number as opposed to smaller, numerous droplets occurring in 
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response to TNF-α treatment in control cells (Fig. 2.7 C).  Again, under these 
conditions, the effect of sustained expression of FSP27 on TNF-α mediated 
lipolysis and lipid droplet phenotypic change occurred despite depletion of 
perilipin (Fig. 2.7 A, B) suggesting that the role of FSP27 is independent of 
perilipin.  Therefore, our data imply that FSP27 depletion is an important 
mechanism for TNF-α action on lipolysis under the conditions of our 
experiments.  However, it remains to be studied how FSP27 confers 
protection against TNF-α effects on lipolysis, and lipid droplet size reduction.  
It can be speculated that FSP27 may form a protective barrier around lipid 
droplets, similar to perilipin, and prevent the access of lipases to the TG core. 
 
The role of FSP27 in lipolysis mediated by β-adrenergic receptor activation is 
different than its role in TNF-α mediated lipolysis.  β-adrenergic receptor 
activation surprisingly increases FSP27 level in a time dependent manner, 
which contrasts with the inhibitory effects of TNF-α described above (Fig.2.9 
A,B).  The increase in FSP27 is due to decreased ubiquitination and 
degradation (Fig. 2.9 C, D, Fig. 2.10 B, C).  We also show that β-adrenergic 
receptor activation signals through canonical PKA pathway and increase in 
intracellular c-AMP, as addition of Forskolin and soluble B-cAMP mimics the 
effect whereas PKA inhibition by KT5720 or PKA depletion using siRNA 
abrogates the effect (Fig.2.11 A, B). However, FSP27 itself doesn’t get 
phophorylated (Fig. 2.11 D, E) suggesting involvement of other mediator 
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protein(s) that get phophorylated in response to catecholamine and stabilizes 
FSP27. A recent study shows that oleic acid treatment of adipocytes also 
increases FSP27 level in a time-dependent manner, and FSP27 stabilization 
after isoproterenol is dependent upon triacylglycerol synthesis (258).  The 
authors in this study hypothesized that isoproterenol mediated lipolysis is 
required to provide FFA for esterification, and the process of FFA 
esterification stabilizes FSP27.  However, our results show that FSP27 
stabilization occurs independent of isoproterenol mediated lipolysis.  It has 
also been shown in the same study that oleic acid treatment of adipocytes 
stabilized FSP27 and has been postulated that the stabilization of FSP27 
after oleic acide treatment is because of TG synthesis because depletion of 
an enzyme required for TG synthesis abrogated the stabilization of FSP27.   
Oleic acid also increases expression of another lipid droplet protein ADRP via 
transcription factor AP1 and a PPAR response element (278).  Thus, the 
increase in FSP27 after oleic acid treatment may involve similar mechanisms 
because the FSP27 promoter also has a PPAR response element.  
Therefore, the mechanism that upregulates FSP27 after oleic acid treatment 
could be different from β-adrenergic pathway, which has no effect on 
transcription.  
 
Nonetheless, the increase in FSP27 after a lipolytic stimuli is counterintuitive, 
and adenovirus mediated expression of FSP27 does not reduce the robust 
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lipolytic effect of isoproterenol (Fig. 2.13 B).  However, it is possible that the 
adenovirus-mediated expression of FSP27 does not have an effect against 
isoproterenol mediated lipolysis because the FSP27 expression and function 
is already at the maximum level.  On the other hand, when FSP27 is depleted 
using siRNA and the adipocytes treated with isoproterenol, there is an 
increased rate of lipolysis at 3hr, correlating with the difference in cellular 
FSP27 levels between Scr and FSP27 siRNA treated adipocytes (Fig. 2.13 
C).  A previous study showed impaired isoproterenol-mediated lipolysis when 
FSP27 was depleted in 3T3-L1 adipocytes (272), however the data was 
presented as a ratio of NEFA released in isoproterenol stimulated condition to 
NEFA released in basal condition, and the decrease in the ratio seen in 
FSP27 silenced condition could be due to increased basal NEFA release as a 
result of FSP27 silencing.  I observed similar increases in glycerol release 
after isoproterenol treatment in FSP27 silenced cells and control cells.  
Furthermore, our results show depletion of FSP27 is not a necessary step for 
isoproterenol mediated lipolysis, however FSP27 depletion using siRNA 
increases the rate of lipolysis in response to isoproterenol.  Thus, I 
hypothesize that up regulation of FSP27 protein is a feedback mechanism to 
restrain excessive lipolysis after strong lipolytic stimuli such as 
catecholamines. 
 
  103 
The data here also suggest that lipolysis and lipid droplet size diminution in 
response to lipolytic agents are different processes.  The decrease in lipid 
droplet size precedes the detectable release of glycerol in adipocytes treated 
with TNF-α (Fig. 2.6 A, B, C, D).  In addition, adenoviral FSP27 expression 
protects against both lipid droplet size decrease and lipolysis in response to 
TNF-α.  Furthermore, FSP27 appears to be a point of divergence between 
TNF-α and β-adrenergic agonist-stimulated lipolysis since expression of 
adenovirus directed FSP27 does not block increased lipolysis induced by 
isoproterenol treatment of adipocytes.  However, adenovirus directed 
overexpression of FSP27 is able to protect against isoproterenol mediated 
lipid droplet reduction.  Thus, our study establishes lipolysis and lipid droplet 
morphology change as distinct processes.  
 
Although FSP27 shares structural and functional similarities with perilipin, 
there is evidence for divergent and non-redundant roles of these two lipid 
droplet proteins.  Structurally, FSP27 was noted to contain domains 
homologous to triacylglycerol shielding and targeting domains in perilipin 
(279).  The phenotypes of the null mice for both proteins include resistance to 
diet induced obesity (215, 216, 234), however perilipin null mice are glucose 
intolerant whereas FSP27 null mice have normal glucose tolerance.  These 
data suggest divergence in the functions of the two proteins in whole body 
metabolism.  Both perilipin and FSP27 can be downregulated by TNF-α, 
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however under our experimental conditions siRNA-mediated knockdown of 
FSP27 led to increased lipolysis despite no significant change in perilipin level 
(Fig. 2.5 A, B, C).  In addition, sustained expression of FSP27 using 
adenovirus to overcome TNF-α effects on FSP27 was able to protect against 
the lipolytic effect of TNF-α in spite of the depletion of perilipin.  Taken 
together, these results show that FSP27, though being similar to perilipin, is 
an important lipid droplet protein with an independent function that is not 
compensated by other lipid droplet proteins such as perilipin. 
 
Although FSP27 is different from perilipin, FSP27 is very similar to another 
lipid droplet protein ADRP.  ADRP, similar to FSP27, targets to lipid droplets, 
and expression of ADRP in fibroblasts, COS, and hepatocytes has been 
shown to promote TG accumulation.  The expression of ADRP increases 
early during adipogenesis, but declines in mature adipocytes as ADRP gets 
replaced by perilipin.  In addition, both FSP27 and ADRP are ubiquitinated to 
target to proteasomal degradation (223).  More interestingly, expression of 
ADRP increases in time dependent manner when adipocytes expressing 
C/EBP-α are treated with isoproterenol (229).  This effect of isoproterenol on 
ADRP expression mirrors the effect of isoproterenol on FSP27.  Moreover, 
the increased levels of ADRP after isoproterenol is associated with lipolysis 
dependent targeting of ADRP to lipid droplets as demonstrated by 
immunofluorescent microscopy (229).  The increased levels of FSP27 after 
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isoproterenol treatment has also been shown to be associated with lipid 
droplets as shown biochemically as well as by immunofluorescent microscopy 
(258).  However, isoproterenol mediated increases in ADRP expression has 
been shown to be independent of PKA activation because isoproterenol 
increases ADRP expression despite the presence of PKA inhibitor (229).  Our 
results show that isoproterenol mediated increase in FSP27 is dependent on 
PKA activation as PKA depletion as well as PKA inhibitor abrogates the effect 
of isoproterenol on FSP27 expression.  Previous studies also show that the 
up regulation of ADRP after isoproterenol treatment also required 
phosphorylation of perilipin (229).  Whether phosphorylation of perilipin is 
required for the effect of isoproterenol on FSP27 remains to be investigated. 
 
In addition to effects of lipid droplet proteins like FSP27 and perilipin, lipolysis 
ultimately depends on the enzymatic activity of lipases such as HSL and 
ATGL.  Lipid droplet TG is hydrolyzed by ATGL into diacylglycerol that in turn 
is acted upon by HSL to release FFAs and glycerol (188, 192).  It has been 
shown that HSL is required for catecholamine stimulated lipolysis (189, 280).  
The localization of HSL to lipid droplets could be perilipin phosphorylation 
independent in basal state and perilipin phosphorylation dependent in 
stimulated condition (219).  However, the lipolytic effect of TNF-α has been 
considered to be due to its effect on various proteins and transcription factors 
that mediate changes in expression of multiple targets, and the requirement 
  106 
 
 
Fig. 2.14.  Regulation of FSP27 by TNF-α  and isoproterenol and their implications on 
lipolysis.  TNF-α depletes FSP27 expression, that leads to formation of smaller lipid droplets 
from unilocular lipid droplet, and increase in lipolysis.  Isoproterenol increases FSP27 
expression, and the increase in FSP27 levels after isoproterenol treatment is required to 
protect lipid droplets from potent lipolytic activity of isoproterenol. 
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 of specific lipases for its action has not been reported.  Here we show that 
ATGL is required for TNF-α to stimulate lipolysis (Fig. 2.8 A).  Furthermore, in 
the absence of lipase ATGL, depletion of FSP27 does not increase lipolysis.  
Thus, both FSP27 and TNF-α require ATGL to mediate their effects on 
lipolysis in adipocytes, similar to the actions of catecholamines.  Important 
questions for future experiments are the molecular mode by which FSP27 
mediates its effect on lipolysis and whether its mechanism of action involves 
direct or indirect engagement of the ATGL and HSL lipases, and/or inhbition 
of their lipase activities. 
 
LIMITATIONS AND FUTURE PERSPECTIVES 
 
All the experiments performed in this thesis work have been done in 3T3-L1 
adipocytes.  3T3-L1 adipocytes in tissue culture are easy to handle, and are 
good model system to investigate metabolic parameters of adipocytes.  
These adipocytes have intact physiology of adipocytes in vivo such as the 
process of adipocyte differentiation, response to insulin, lipogenesis, and 
lipolysis.  In addition, they make a model system in which hypothesis can be 
tested fairly quickly in physiologically relevant manner whereas investigating 
same questions in an animal model would take considerably more time.  
However, it needs to be acknowledged that adipocytes in tissue culture is 
deprived of the whole body milieu, and thus the results obtained in 3T3-L1 
  108 
adipocytes need to be confirmed in in vivo model.  We have observed that 
FSP27 expression increases during adipogenesis in vitro in 3T3-L1 
adipocytes.  Therefore, we may postulate that FSP27 will increase with 
obesity that is associated with increased fat mass.  However, FSP27 
expression decreases in ob/ob obese mice.  This illustrates the importance of 
reconfirming the results obtained from in vitro model system in in vivo system 
also.    
 
The data presented in this thesis indicate that the lipolytic actions of TNF-α 
and isoproterenol can be regulated through modulation of the FSP27 levels in 
adipocytes.  It is evident from these studies that during TNF-α mediated 
lipolyis, depletion of FSP27 is a critical event, which if abrogated can impede 
the process of lipolysis also.  On the other hand, up regulation of FSP27 in 
response to isoproterenol is a possible intrinsic mechanism to protect lipid 
droplets from the potent lipolytic effects of isoproterenol.  However, it remains 
to be investigated in detail how FSP27 protects lipid droplets against lipolysis.  
It can be hypothesized that FSP27 covers lipid droplets to form a protective 
mechanical barrier to prevent the access of lipases to the TG core.  It is also 
possible that FSP27 may inhibit the lipase activity of HSL and/or ATGL with or 
without direct interaction with these lipases.   
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Previous studies suggest that FSP27 promotes the formation of unilocular 
lipid droplets in adipocytes.  Consistently, in my experiments, overexpression 
of FSP27 using an adenovirus resulted in formation of fewer and larger lipid 
droplets even in presence of TNF-α and isoproterenol, which are known to 
cause lipid droplet size diminution.  This raises an interesting question 
whether FSP27 prevents the fragmentation of existing lipid droplets or 
promotes the fusion of smaller lipid droplets to form larger lipid droplets.  It 
would be informative to use live cell imaging to study the characteristics and 
behaviour of lipid droplets in adipocytes containing or lacking FSP27.  
 
Another important area for future investigations is to elucidate the mechanism 
of isoproterenol mediated FSP27 stabilization.  Our results show that 
isoproterenol signals via canonical PKA pathway, and increases in cAMP 
levels to stabilize FSP27.  However, FSP27 itself may not be phosphorylated 
suggesting involvement of other intermediate protein(s) that get(s) 
phosphorylated by PKA.  It can be speculated that the intermediate protein(s), 
through direct or indirect mechanism, may target FSP27 to the lipid droplets 
harboring fatty acid reesterification, and the process of reesterification 
stabilizes FSP27.  One of the possible candidates for such intermediate 
protein is the heat shock protein (HSP).  Previous studies on HSPs have 
suggested their role in regulation of protein stability. In addition, HSPs can be 
possible targets for PKA mediated phophorylation because evidences 
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suggest that HSPs have several post-translational modifications including 
phophorylation.  The unpublished data from our lab has identified HSP86 as a 
protein interacting with FSP27, and thus would be interesting to investigate if 
HSP86 gets phosphorylated by PKA, and plays a role in mediating effect of 
catecholamine on FSP27.    
 
Although our data strongly show the involvement of FSP27 in lipolysis 
mediated by various stimuli in 3T3-L1 adipocytes, it would be preferable to 
repeat the results in vivo.  It remains to be determined if transgenic mice 
engineered to express FSP27 specifically in adipose tissue will have 
decreased lipolysis in response to the lipolytic stimuli of TNF-α and 
isoproterenol.  
 
Ultimately, it is imperative to demonstrate the observations from in vitro and 
rodent model are consistent in human also.  Nonetheless, our study identifies 
modulation of FSP27 as an important mode by which TNF-α and 
isoproterenol regulate lipolysis in adipocytes. 
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Chapter III 
DISCUSSION 
In the present era of obesity and diabetes epidemic, studies researching the 
pathophysiology of insulin resistance in obesity and diabetes, and thereby 
contributing to find a cure for diabetes have paramount importance.  One of 
the emerging hypotheses in the field of insulin signaling is the role of FFAs in 
pathogenesis of insulin resistance.  Thus, there has been increasing interest 
in understanding the metabolism and regulation of free fatty acids.  The key 
players in regulation of FFAs are the lipid droplet proteins that serve to store 
FFAs in the form of TGs in lipid droplets mainly in adipocytes, and various 
lipolytic stimuli that signal to hydrolyze stored TGs to release FFAs.  This 
study examines the regulation of a novel lipid droplet protein, FSP27 by two 
major lipolytic stimuli, TNF-α and catecholamine, to modulate lipolysis in 
adipocytes.    
 
Although FSP27 has been discovered in 1992 as an adipocyte-specific gene 
(262), FSP27 has emerged as lipid droplet protein only recently after our lab 
and others showed FSP27 to target to lipid droplets (233, 234, 249). The role 
of FSP27 in lipid metabolism is supported by studies that show the 
expression of FSP27 promotes lipid accumulation in oleic acid treated COS 
cells and preadipocytes whereas depletion of FSP27 using siRNA leads to 
degradaton of stored lipid leading to lipolysis and lipid droplet dispersion (233, 
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234).  Moreover, FSP27 null mice are resistant to diet-induced obesity, and 
insulin resistance (234) suggesting the role of FSP27 in maintaining insulin 
sensitivity.  Despite the growing attention to FSP27, the regulation of FSP27 
and its role in lipid metabolism is still poorly understood. 
 
Regulation of FSP27 
This study demonstrates that FSP27 is a PPARγ responsive gene (231).  
PPARγ is considered to be the master regulator of adipogenesis, and is 
upregulated during adipogenesis.  PPARγ controls the expression of 
numerous adipocyte-specific genes involved in lipid metabolism.  Studies 
show that FSP27 is also upregulated during adipogenesis, and the increase 
in FSP27 expression mirrors the increase in PPARγ expression during the 
adipocyte differentiation process.  Consistently, the expression of FSP27 
increases in ob/ob mice upon treatment with PPARγ agonist rosiglitazone 
(231, 264).  It has now been shown that PPARγ2 binds to PPARγ response 
element in FSP27 promoter, and drives the expression of FSP27  (246).  
FSP27 is also found to be PPARγ target gene in hepatocytes, and promotes 
hepatic steatosis in leptin-deficient mice (264).  However, the mechanism of 
transcriptional control of FSP27, and the role of other transcription factor and 
co-factors remains to be investigated in detail. 
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In addition to the regulation of FSP27 at transcriptional level, FSP27 can also 
be regulated at translational or post-translational level.  This study and 
recently published study show that FSP27 has an extremely short half-life of 
approximately 15 min (258).  The half-life of FSP27 is short because it is 
ubiquitinated, and then degraded via proteasome.  Regulation of FSP27 
stability by ubiquitination is similar to the regulation of FSP27 isoform, CIDEA, 
and other lipid droplet proteins, perilipin and ADRP (209, 223, 238).  
Alteration of ubiquitin modification of FSP27 is one way how cellular FSP27 
may be regulated.  It is possible that the half-life of FSP27 can be much 
longer than 15 min when FSP27 is bound to lipid droplets or to proteins 
involved in fatty acid reesterification because Nian et. al. recently reported 
fatty-acid- re-esterification dependent stabilization of FSP27 in adipocytes 
after isoproterenol treatment.  Another well-studied lipid droplet protein, 
perilipin, also has a short half-life when not bound to lipid droplet, but is 
stabilized to half-life of 40 hr when bound to lipid droplets (208).  It remains 
open to exploration whether similar phenomenon exists to stabilize FSP27. 
 
Depletion of FSP27 is critical for TNF-α to mediate lipolysis 
TNF-α is an inflammatory cytokine that is shown to be elevated in adipocytes 
in obesity and inflammation (270) and also in circulation of diabetic NOD mice 
(269).  Although TNF-α has myriad of effects that can lead to development of 
insulin resistance, one of the hypotheses is that the lipolytic effect of TNF-α 
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increases circulating FFAs that contribute to the development of insulin 
resistance.  Prior studies show that TNF-α mediates lipolysis in adipocytes 
through multiple pathways including depletion of lipid droplet coat protein, 
perilipin, and inhibition of phosphodiesterase enzyme (174, 176).  Here we 
show that depletion of FSP27 is a novel and critical pathway through which 
TNF-α mediates lipolysis in adipocytes. 
 
TNF-α rapidly decreases FSP27 as observed by others and us (235) possibly 
due to the negative effect of TNF-α on PPARγ, the transcription factor that 
controls FSP27.  However, the effect of TNF-α  on FSP27 mRNA degradation 
cannot be excluded with present data.  The rapid decrease in FSP27 protein 
after TNF-α treatment reflects the decrease in FSP27 mRNA.  The effect of 
TNF-α on FSP27 protein may be primarily due to the effect on FSP27 
transcription.  Nevertheless, expression of FSP27 via adenovirus to overcome 
TNF-α mediated FSP27 depletion is able to protect against lipolytic effect of 
TNF-α in adipocytes.  The adenovirus directed expression of FSP27 is also 
able to overcome the TNF-α mediated lipid droplet size diminution, consistent 
with our earlier results showing FSP27 promotes the formation of unilocular 
lipid droplets. TNF-α mediated lipolysis also involves perilipin, a lipid droplet 
protein that has similar role in lipolytic effect of TNF-α (174).  However careful 
analysis of perilipin in our studies show that protective effect of FSP27 
against lipolytic actions of TNF-α is independent of perilipin.  
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Although it has been observed previously that TNF-α causes lipid droplet size 
diminution, and increase in lipolysis, the temporal sequence of these events 
are not documented.  This study show that TNF-α mediated rapid depletion of 
FSP27 is followed by lipid droplet size diminution that leads to increase in 
glycerol release.  The depletion of FSP27 can be the key event that leads to 
lipid droplet dispersion, thereby increasing the total surface area of lipid 
droplets, and increase the access of lipases such as ATGL to the stored TGs.  
Once ATGL, the lipase necessary for TNF-α mediated lipolysis, gain access 
to the stored lipid, the enzymatic degradation of TGs releases FFAs and 
glycerol.  Thus, it is observed that the increase in glycerol release after TNF-α 
treatment of adipocytes lag behind the TNF-α mediated FSP27 depletion, and 
lipid droplet dispersion. 
 
The work presented here gives a new insight to the mechanism of TNF-α 
mediated lipolysis in adipocytes.  These results suggest that FSP27 can be a 
potential target that can be modulated to overcome the TNF-α mediated 
lipolysis, and insulin resistance. 
  
Isoproterenol mediated stabilization of FSP27 
The other important stimuli that signal to lipolysis in adipocyte are 
catecholamines.  Catecholamines, released in circulation during fasting, 
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stimulate β-adrenergic receptors in adipocytes causing robust lipolysis to 
release FFAs that act as fuel to other cell types.  We report here that 
catecholamines paradoxically increase cellular FSP27 levels by delaying its 
proteasomal degradation. 
 
The recently published study and our study (258) show that cellular FSP27 
levels increase after isoproterenol treatment of adipocytes.  Their study and 
ours show that isoproterenol mediated increase in FSP27 is due to decreased 
ubiquitination and degradation of FSP27.  The work in this thesis further show 
that isoproterenol signals via canonical PKA pathway to stabilize FSP27, but 
the activation of PKA by isoproterenol does not phosphorylate FSP27 unlike 
perilipin that gets phosphorylated by PKA (181).  Nian et. al. has reported that 
PKA mediated lipolysis releases FFAs that undergoes reesterification and the 
process of reesterification stabilizes FSP27.  However, we show that 
isoproterenol stabilizes FSP27 even when lipolytic effect of isoproterenol is 
blunted by siRNA  mediated ATGL knock-down.  
 
We have also examined the functional implication of isoproterenol mediated 
FSP27 stabilization in adipocytes.  Previous study has shown impaired 
isoproterenol-mediated lipolysis when FSP27 was depleted in 3T3-L1 
adipocytes (272), however the data has been presented as a ratio of non-
esterified fatty acids (NEFA) released in isoproterenol stimulated condition to 
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NEFA released in basal condition, and the decrease in the ratio seen in 
FSP27 silenced condition can be due to increased basal NEFA release due to 
FSP27 silencing.  We show robust lipolysis in response to isoproterenol even 
when FSP27 is silenced using siRNA and additionally, these results show the 
rate of lipolysis after isoproterenol treatment of adipocytes is increased when 
the effect of isoproterenol on FSP27 stabilization is inhibited by knocking 
down FSP27 using siRNA.  This suggests that FSP27 functions to protect 
against the catecholamine mediated lipolysis, and the stabilization of FSP27 
by catecholamine could be a feedback mechanism to prevent excessive 
lipolysis after catecholamine treatment.  Although there are conflicting results 
that show adenovirus directed expression of FSP27 to a higher level does not 
protect against the robust lipolytic effect of isoproterenol, it can be debated 
that isoproterenol treatment alone has already increased FSP27 to its 
maximal functional level, and thus additional FSP27 expression does not 
have any supplementary protective effect against isoproterenol mediated 
lipolysis. 
 
Though adenovirus directed FSP27 expression does not diminish robust 
lipolytic effect of isoproterenol, the increased FSP27 levels interestingly 
protect against isoproterenol mediated dispersion of lipid droplets.  Thus, this 
study confirms previous studies indicating isoproterenol mediated lipolysis 
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and lipid droplet dispersion are two distinct and different events, and the lipid 
droplet dispersion is not a prerequisite for lipolysis (183). 
 
The work presented here taken together with the study done by Nian et. al. 
shows that FSP27 is a remarkably short-lived protein with a half-life of 
approximately 15 mins, and is ubiquitinated to target to proteasome.  
Isoproterenol delays the degradation of FSP27 and stabilizes FSP27.  This 
thesis work furthers Nian et. al. study showing that isoproterenol mediated 
stabilization of FSP27 signals via canonical PKA pathway and increase in 
intracellular cAMP; but is independent of isoproterenol mediated lipolysis.  
The work presented here also attempts to tackle the physiological 
significance of change in FSP27 levels, and shows that the cytokine TNF-α 
depletes FSP27 to mediate lipolysis whereas isoproterenol stabilizes FSP27 
to restrain its own potent lipolytic activity.   
 
FSP27 is an emerging lipid droplet protein with an important function in lipid 
metabolism.  The effect of FSP27 on inhibiting lipolysis and promoting TG 
accumulation in unilocular lipid droplets is not only seen in vitro and in rodent 
models, but also is observed in human adipocytes (257).  In addition, it has 
been reported that a patient with homozygous mutation in FSP27/CIDEC has 
partial lipodystrophy, and insulin resistant diabetes (251).  Our lab also has 
reported the decrease in FSP27/CIDEC in the insulin resistant obese patients 
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compared to the insulin sensitive obese ones (231).  FSP27/CIDEC is one of 
the genes that is reported to be upregulated in patients in response to the 
therapeutic treatment of type II diabetes with rosiglitazone or metformin (247).  
Taken together, these evidences reinforce the importance of FSP27/CIDEC in 
lipid metabolism, and insulin sensitivity in humans consistent with the data 
obtained from in vitro and rodent model.  Moreover, considering the protective 
effects of FSP27 against lipolysis, and insulin resistance, FSP27 could be a 
possible therapeutic target for treatment of type 2 diabetes mellitus. 
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